

Medical Abortion

This clinical practice guideline has been prepared by the Induced Abortion Guidelines Working Group, and approved by the Executive and Board of the Society of Obstetricians and Gynaecologists of Canada.

PRINCIPAL AUTHORS

Dustin Costescu, MD, Hamilton ON (co-chair)
 Edith Guilbert, MD, Quebec QC (co-chair)
 Jeanne Bernardin, MD, Moncton NB
 Amanda Black, MD, Ottawa ON
 Sheila Dunn, MD, Toronto ON
 Brian Fitzsimmons, MD, Vancouver BC
 Wendy V. Norman, MD, Vancouver BC
 Helen Pymar, MD, Winnipeg MB
 Judith Soon, PhD, Vancouver BC
 Konia Trouton, MD, Victoria BC
 Marie-Soleil Wagner, MD, Montréal QC
 Ellen Wiebe, MD, Vancouver BC

SPECIAL CONTRIBUTORS

Karen Gold, SW, Toronto ON
 Marie-Ève Murray, MD, Montréal QC

ACKNOWLEDGEMENTS

Beverly Winikoff, New York, NY, USA
 Matthew Reeves, Washington, DC, USA
 Disclosure statements have been received from all authors and none declared any conflicts of interest.

Key Words: medical abortion, induced abortion, early abortion, mifepristone, misoprostol

<http://dx.doi.org/10.1016/j.jogc.2016.01.002>

Abstract

Objective: This guideline reviews the evidence relating to the provision of first-trimester medical induced abortion, including patient eligibility, counselling, and consent; evidence-based regimens; and special considerations for clinicians providing medical abortion care.

Intended Users: Gynaecologists, family physicians, registered nurses, midwives, residents, and other healthcare providers who currently or intend to provide pregnancy options counselling, medical abortion care, or family planning services.

Target Population: Women with an unintended first trimester pregnancy.

Evidence: Published literature was retrieved through searches of PubMed, MEDLINE, and Cochrane Library between July 2015 and November 2015 using appropriately controlled vocabulary (MeSH search terms: Induced Abortion, Medical Abortion, Mifepristone, Misoprostol, Methotrexate). Results were restricted to systematic reviews, randomized controlled trials, clinical trials, and observational studies published from June 1986 to November 2015 in English. Additionally, existing guidelines from other countries were consulted for review. A grey literature search was not required.

Values: The quality of evidence in this document was rated using the criteria described in the Report of the Canadian Task Force for Preventive Medicine rating scale (Table 1).

Benefits, Harms and/or Costs: Medical abortion is safe and effective. Complications from medical abortion are rare. Access and costs will be dependent on provincial and territorial funding for combination mifepristone/misoprostol and provider availability.

Summary Statements

Introduction

1. In countries where mifepristone is approved, women have improved access to medical abortion; however, abortion rates do not increase. (Level II-3)
2. Women who can choose their method of abortion have higher satisfaction rates. (Level II-1)

Pre-procedure care

3. In the absence of readily accessible ultrasound, gestational age can be estimated using last menstrual period (LMP), clinical history, and physical examination, in women who are certain of the date of their LMP. Ultrasound is needed when uncertainty remains. (Level II-2)
4. The probability of ectopic pregnancy among women requesting abortion is consistently lower than in the general population. (Level II-3)

J Obstet Gynaecol Can 2016;38(4):366-389

Copyright © 2016 The Society of Obstetricians and Gynaecologists of Canada/La Société des obstétriciens et gynécologues du Canada. Published by Elsevier Inc. All rights reserved.

This document reflects emerging clinical and scientific advances on medical abortion, on the date issued, and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Local institutions can dictate amendments to these opinions. They should be well documented if modified at the local level. None of these contents may be reproduced in any form without prior written permission of the SOGC.

Table 1. Key to evidence statements and grading of recommendations, using the ranking of the Canadian Task Force on Preventative Health Care

Quality of evidence assessment*	Classification of recommendations†
I Evidence obtained from at least one properly randomized controlled trial	A. There is good evidence to recommend the clinical preventive action
II-1 Evidence from well-designed controlled trials without randomization	B. There is fair evidence to recommend the clinical preventive action
II-2 Evidence from well-designed cohort (prospective or retrospective) or case-control studies, preferably from more than one centre or research group	C. The existing evidence is conflicting and does not allow to make a recommendation for or against use of the clinical preventive action; however, other factors may influence decision-making
II-3 Evidence obtained from comparisons between times or places with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of treatment with penicillin in the 1940s) could also be included in the category	D. There is fair evidence to recommend against the clinical preventive action
III Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees	E. There is good evidence to recommend against the clinical preventive action
	F. There is insufficient evidence (in quantity or quality) to make a recommendation; however, other factors may influence decision-making

*The quality of evidence reported in these guidelines has been adapted from The Evaluation of Evidence criteria described in the Canadian Task Force on Preventive Health Care.

†Recommendations included in these guidelines have been adapted from the Classification of recommendations criteria described in The Canadian Task Force on Preventive Health Care.

Medical abortion regimens

5. There is limited evidence regarding teratogenicity of mifepristone, but overall the risk appears to be low. (Level III)

6. Misoprostol is a known teratogen when used in the first trimester of a pregnancy. (Level II-2)
7. The risk of teratogenicity is high with the use of methotrexate. (Level II-3)
8. Oral mifepristone 200 mg and buccal misoprostol 800 µg is 95% to 98% effective up to 49 days after last menstrual period. The risk of ongoing pregnancy is less than 1%. (Level I)
9. Oral mifepristone 200 mg and buccal, vaginal, or sublingual misoprostol 800 µg is 87% to 98% effective up to 63 days after last menstrual period. The risk of ongoing pregnancy is less than 3.5%. (Level I)
10. Intramuscular/oral methotrexate and vaginal/buccal misoprostol is 84% to 97% effective up to 63 days after last menstrual period. The risk of ongoing pregnancy is 0.4% to 4.3%. (Level I)

Providing medical abortion

11. There is no evidence to support or refute the routine administration of Rh immunoglobulin to Rh negative women who undergo medical abortion before 49 days last menstrual period. (Level III)
12. There is no strong evidence supporting routine antibiotic prophylaxis for medical abortion. (Level II-2)
13. Medical abortion is associated with bleeding, which is often heavier than a menstrual period, and with potentially severe cramping. (Level III)
14. Prophylactic ibuprofen administration does not provide superior pain control compared with as-needed dosing in women undergoing medical abortion. (Level I)

Post-abortion care

15. Follow-up rates are similar for both remote and in-clinic visits. (Level II-2)
16. When both women and their clinician believe successful expulsion has taken place, based on history alone, complete abortion is likely. (Level II-2)
17. Either ultrasound and/or serial bhCG measurements provide definitive evidence of pregnancy termination. (Level I)

ABBREVIATIONS

ACOG	American College of Obstetrics and Gynecology
βhCG	beta human chorionic gonadotropin
COC	combined oral contraceptives
DMPA	depot medroxyprogesterone acetate
EP	ectopic pregnancy
GA	gestational age
IPV	intimate partner violence
IUD	intrauterine device
IUP	intrauterine pregnancy
LMP	last menstrual period
MA	medical abortion
MIFE	mifepristone
MIFE200/ MISO800	combination mifepristone and misoprostol, taken as directed in the product monograph
MISO	misoprostol
MTX	methotrexate
NAF	National Abortion Federation
NSAIDs	non-steroidal anti-inflammatory drugs
POP	progestin-only pill
PPFA	Planned Parenthood Federation of America
PUL	pregnancy of unknown location
RPOC	retained products of conception
SA	surgical abortion
SFP	Society of Family Planning
WHO	World Health Organization

18. A fall of beta human chorionic gonadotropin levels of 80% or more from pre-treatment to first follow-up at 7 to 14 days is indicative of a completed medical abortion. (Level II-2)
19. If ultrasound is used to assess completion of a medical abortion, endometrial thickness alone is not predictive of the need for subsequent surgical intervention. (Level II-2)
20. Retained products of conception requiring aspiration are more common in medical compared with surgical abortion. (Level II-2)
21. A second dose of misoprostol may lead to completion of a medical abortion when there is a retained gestational sac or an ongoing pregnancy. (Level III)
22. Severe complications following medical abortion are rare. (Level II-2)
23. Ovulation may occur as soon as 8 days after starting the medical abortion procedure. (Level III)
24. Insertion of intrauterine device at the follow-up visit after medical abortion is associated with higher insertion rates and equivalent expulsion rates compared with delayed insertion. (Level I)

Recommendations

Introduction

1. Women who are eligible for medical abortion should be counselled on the availability of both medical and surgical options. (Level II-2A)

Pre-procedure care

2. When communicating with a woman who has an unintended pregnancy, health care providers should use appropriate non-judgemental and nondirective language, preferably with additional written or online material, and should ensure a confidential environment. (Level III-A)
3. Health care providers uncomfortable with abortion counselling or provision must promptly refer the woman to another health care provider/facility or provide information on where she may be able to access abortion care. (Level III-A)
4. Women seeking an abortion should have the capacity to provide voluntary informed consent. Health care providers should counsel women on the proposed intervention and alternatives, outcomes, and risks. (Level III-A)
5. Providers should use a reliable method to confirm that a pregnancy is at appropriate gestational age for effective and safe medical abortion. (Level II-2A)
6. Women should be informed that medical abortion carries a small increased risk of additional intervention compared with surgical abortion. (Level II-2B)

Medical abortion regimens

7. Only evidence-based regimens should be used to perform medical abortion. (Level I-A)

8. Mifepristone 200 mg oral and misoprostol 800 µg buccal/vaginal/sublingual is the regimen of choice for medical abortion up to 70 days among eligible women. (Level I-A)

Providing medical abortion

9. Rh immunoglobulin is recommended to Rh negative women undergoing medical abortion beyond 49 days from last menstrual period and may be offered before 49 days. (Level III-C)
10. Women who have risk factors for ectopic pregnancy and/or clinical symptoms, such as abdominal pain and vaginal bleeding, should have an ultrasound and be adequately followed. (Level III-A)
11. Women who have a pregnancy of unknown location and request medical abortion should receive abortion care without delay provided that they have no clinical symptoms of ectopic pregnancy (EP). If the transvaginal ultrasound demonstrates an empty uterus and the bhCG is > 2000 IU/L, the woman should be evaluated for an EP and appropriate counselling, investigations, and follow-up should be arranged. (Level III-B)
12. All women with a pregnancy of unknown location, and women who have not had a pre-abortion ultrasound, must have serial bhCG levels until ectopic pregnancy has been excluded and/or the abortion is complete. (Level III-A)

Post-abortion care

13. All women undergoing medical abortion should have a follow-up assessment to confirm completion of the abortion. (Level II-2A)
14. A reliable method of follow-up should be used. This can be done in clinic or remotely using ultrasound and/or serial bhCG measurements combined with clinical history. (Level II-2A)
15. A fall of bhCG levels of less than 80% from pre-treatment to the first follow-up at 7 to 14 days requires further investigation/management/follow-up/referral. (Level II-2A)
16. Providers should inform women about symptoms and signs of complications and give them clear information on emergency care. (Level III-A)
17. Women with ongoing pregnancy at first follow-up after the start of a medical abortion with mifepristone/misoprostol should be offered repeat misoprostol or surgical evacuation. (Level III-A)
18. Women with ongoing pregnancy 14 to 21 days after the start of a medical abortion with mifepristone/misoprostol should be offered surgical evacuation. (Level III-A)
19. Surgical abortion is recommended for women with ongoing pregnancy after methotrexate/misoprostol for attempted medical abortion. (Level III-A)
20. If a woman wishes to start a hormonal method of contraception, it should be started as soon as possible after taking misoprostol. (Level III-B)
21. If a woman wishes to start using an intrauterine device, it should be inserted at the follow-up visit after medical abortion, once completion of the abortion is confirmed. (Level I-B)

INTRODUCTION

Definition and Scope

Medical abortion (MA) is the process by which a pregnancy is voluntarily interrupted through the administration of one or more medications. In July 2015, Health Canada approved the first combination drug regimen (mifepristone/misoprostol) for MA. These guidelines review the evidence-based regimens and care pathway of MA for first trimester pregnancies. A separate surgical abortion (SA) guideline will be developed by the working group; however, the pre-abortion section applies also to women undergoing SA. This guideline does not address abortion or induction beyond the first trimester, although a Society of Family Planning Guideline on this topic does exist.¹ Unless otherwise stated, “abortion” refers to first trimester induced abortion.

Access to Abortion Services

Abortion is the second most common reproductive health procedure, experienced by 31% of Canadian women.² Between 1991 and 2005, roughly 100 000 abortions occurred annually in Canada.³ Since 2006, the number of abortions has decreased slightly, but incomplete reporting in recent years makes comparisons difficult.^{4,5} Based on data reported to the Canadian Institute for Health Information (CIHI),⁵ 4% of abortions are reported as MA. Detailed abortion service data were collected in a national survey in 2012, representing 83% of abortion facilities across Canada and 91% of the abortions reported by CIHI.^{6,7} In this survey, MA represented 3.8% of all first trimester abortions reported (2706 procedures).⁶

Mifepristone (MIFE) was first approved in France and China in 1988 and is currently approved in approximately 60 countries.⁸ MIFE has facilitated access to safe, private, and effective abortion service.^{9–11} Because MIFE has only recently been approved in Canada, physicians wishing to offer MA have not had access to this paragon of treatment.¹²

In countries where MIFE is approved, abortion rates do not increase—the proportion of abortions that are MA increases, ranging between 30% and 80%.^{13–18} MA increases access in areas where women cannot reach surgical services, which tend to be concentrated in large centres.^{7,19–22}

Patient Preference

In studies where women were given the choice between MA and SA,^{23–32} 35% to 84% of women chose MA. Reasons for choosing MA include avoidance of surgery and anesthesia, avoidance of pain, perceived safety, efficacy, privacy, a “natural” approach, and the ability to

accommodate other commitments (e.g., work or home tasks).^{23–26,31–36} Reasons for not choosing MA include the requirement for several visits, lack of immediacy, dosing schedule, and swallowing pills.^{23–25,31,32,35} Some women expressed fear of toxicity, pain, or side effects of the medication,^{23,24,35} anxiety over the start of the process,²³ and fear of potential psychological sequelae.²⁴

Most women who selected MA would opt for MA again (63% to 96%),^{23–25,27,31,33–39} similar for women who select SA.^{23,25–28,32,37,39,40} In studies where women chose their method of abortion, satisfaction was higher than in those where treatment was assigned;^{24,26–28,32,37,40} therefore, women should be offered both options.

Medical Abortion Providers

In a 2012 survey of Canadian providers, 62 of 212 physicians offered MA (29.2%).⁶ Most (84%) used a methotrexate/misoprostol (MTX/MISO) regimen.⁶ As mifepristone/misoprostol (MIFE/MISO) providers will be required to complete a registration process, new data will be available to quantify MA providers.

Abortion services to date largely occur in surgical facilities (hospital or clinic-based).^{4,5} Mifepristone presents an opportunity to increase the provision of abortion care in settings that do not identify as an abortion facility. It may also mitigate some of the logistical challenges reported by rural and hospital-based providers.

Safety

Despite cases of violence against abortion providers in North America, Canadian providers report few episodes of stigma or harassment in recent years.⁴¹ Two thirds of Canadian abortion facilities reported no episodes of harassment in 2012, and, of those reporting harassment, 22% experienced only picketing without obstruction.⁷ Eighteen percent of Canadian providers reported personally experiencing harassment.⁴¹

Women seeking abortion care may also experience stigma and harassment. The most significant source of stigma and harassment is the partner involved with the pregnancy. Intimate partner violence (IPV), including reproductive coercion, is linked to the need for abortion in many ways. Reproductive coercion includes explicit attempts to impregnate a partner against her will, control outcomes of a pregnancy, coerce a partner to have unprotected sex, and interfere with contraceptive methods.⁴² IPV increases risk for abortion, unintended pregnancy, and sexually transmitted infection.^{43–46} In turn, unintended pregnancy is implicated in exacerbation of ongoing IPV.^{42,47–52}

PRE-ABORTION CARE

Women who are contemplating abortion require timely care. Pre-abortion care consists of options counselling, medical evaluation, and, when required, prompt referral (e.g., if the gestational age exceeds clinic limits or if pregnancy is abnormal). The following section applies for women undergoing either MA or SA.

Pregnancy Options Counselling

Most women presenting for counselling have already made their decision, and few change their minds.^{53–55} Counselling is useful when a woman is ambivalent or emotionally distressed. There is no universal or evidence-based method to counsel a patient presenting with an unintended pregnancy.^{10,56–58} Counselling may be provided by any appropriately trained professional and should be tailored to the woman’s needs. Some providers focus on counteracting abortion stigma, others focus on emotional support, and others do not feel it is their place to question a woman’s decision or thought process. The professional or facility providing counselling must be available to promptly organize any decision the patient might take.

Counselling before abortion typically includes a review of (1) pregnancy options (abortion, term pregnancy, adoption); (2) abortion methods; (3) risks and benefits; (4) supports and confirmation that the decision is voluntary; (5) emotional needs, values, and coping abilities; and (6) contraceptive options.^{10,58–61}

A nonjudgemental, nondirective approach in a confidential environment must be provided. Patient-level language, supplemented with written resources, should be used. No time pressure should be placed on the woman, but it is essential to communicate the gestational age limits for medical abortion and surgical abortion (clinic and jurisdiction-specific), and that risks may change with advancing gestational age (i.e., dilation and evacuation vs. aspiration curettage).

Mandatory pre-abortion counselling exists in over half of US states and some European countries.⁶² Although some studies suggest that women find it helpful, others suggest that counselling may be unwanted, unnecessary, and costly.^{63–65}

Referral

The Canadian Medical Association, the SOGC, the Canadian Medical Protective Association, and the World Health Organization (WHO) have all issued statements or documents regarding the right for women to access abortion safely and promptly and the need for physicians to provide

the requested information.^{59,66–69} Clinicians should refer patients to known abortion providers/facilities, virtually all of which will facilitate any referral that is requested.^{70,71} Some Crisis Pregnancy Centres offer services to women with unplanned pregnancies but often give inaccurate or misleading medical information regarding abortion risks, and object to providing abortion referrals, causing delay and harm.⁷²

Centralized referral systems reduce delays in counselling and abortion services.⁷³ A toll-free resource line in British Columbia has been shown to improve access and overcome barriers for women seeking abortion services. It also provided benefits for health care planning and monitoring of provincial service delivery and gaps at low costs.⁷⁴ Ideally, public abortion services should be easily identified and accessible by self-referral.

Factors Affecting the Selection of the Method of Abortion

The decision between MA and SA requires an understanding of both options, and a review of factors that affect method selection. As shown in Table 2, particular features of each option must be discussed with the woman.

Simply listing each method is insufficient, as there may be wait times, travel, access, and economic realities that make

Table 2. Principal features of medical abortion versus surgical abortion

Medical abortion	Surgical abortion
Avoids surgery	Surgical procedure
Can take days (with MIFE/MISO) to weeks (with MTX/MISO) to complete	Completion within 5–10 minutes followed by 30–60 minutes observation time
May be painful	Usually less painful as anesthesia offered
≥ 95% success rate within 1–3 weeks	99% success rate
Much heavier bleeding than with a period	Less bleeding, usually light
2–3 visits for assessment, administration of medication, and follow-up (sometimes more with MTX/MISO)	Often 1 visit, sometimes 2 if assessment is separate
May be cost for medications	No cost if have provincial insurance
Do not need to involve someone to take you to clinic visits, but helpful to have someone with you	May require someone to drive you depending on anesthesia offered

MIFE/MISO: mifepristone/misoprostol; MTX/MISO: methotrexate/misoprostol.

Table 3. Questions to help women identify which option to choose

	Questions to ask	Medical	Surgical
Social factors	Have you confided in anyone?	Helpful to have someone with you	Support from professionals at clinic or hospital
	Would you like someone with you?	Support person can be present	Usually alone in the procedure room
	Do hospitals or clinics bother you?	Most visits avoid invasive examinations	Need to be in facility on day of procedure
	Do you have a ride to the clinic/hospital/office?	No need for a ride	Need a ride following anesthesia
Logistics	Where is the nearest clinic?	May be closer to home	Often only in large centres
	Where is the nearest emergency facility?	Women should have access to emergency care over 7–14 days	Many surgical facilities are affiliated with a hospital or can provide urgent aspiration
	What is the wait time?	Usually within days	Variable
	Do I need time off work?	For 1 to 2 days, during expulsion	Day of surgery
	Will it cost anything?	May be cost for drugs if not covered	No charge if Canadian resident—certain exceptions for in-clinic procedures
	Do you need a referral?	Often performed by primary care, but may require referral	Self-referral common, but referral may be needed in smaller centers
	Experience	Have you had a medical abortion before?	63%–96% of those having MA will choose it again
Have you had a surgical abortion before?			60%–100% of those having surgery would choose again
Do you have concerns about an experience of a close friend/relative?		May influence the woman's choice	May influence the woman's choice
Expectation	Does the idea of bleeding at home bother you?	Heavy bleeding	Much less bleeding
	Does the idea of surgery bother you?		Fear of surgery leads to anxiety and poor tolerance
	Is it important to reduce/blunt your memory of this experience?	Supportive family and friends can help, but the abortion is frequently obvious	The situation that led to the abortion may be traumatic. Surgery with anesthesia may help
	Do you have excessive pain with periods, or how do you tolerate them?	Pain is inherent to MA but can be reduced by analgesics	Pain can be reduced by anesthesia
	Is it important that no one else know about the abortion?	It may be difficult to conceal pills, but abortion may be passed off as a miscarriage	As there is only one clinic visit, it may be easier to conceal or explain in some circumstances

MA: medical abortion.

one option unattainable (Table 3). Knowing the availability of MA and SA in one's present location is important.⁷⁵

Obtaining Informed Consent

Consent for any procedure must be voluntary, unbiased, informed, and the person giving the consent must have the capacity to do so.^{76,77}

For MA, a woman should be informed of the following specific points:

1. MA involves using drugs to end a pregnancy.

2. MA with mifepristone 200 mg oral and misoprostol 800 µg buccal/vaginal/sublingual regimens are considered as effective and safe as surgical abortion before 49 days following the last menstrual period (LMP) and are highly effective up to 70 days LMP.^{78–85}

3. An evidence-based regimen must be used; however, women should be informed when the regimen is “off-label.”

4. MA is considered irreversible.⁸⁶

5. For combination MA protocols, all drugs need to be taken as directed.

6. MA does not completely eliminate the need for surgical evacuation. In the event of ongoing pregnancy, a SA is recommended, as these drugs may be teratogenic.
7. Women should have access to urgent medical care for the next 7 to 14 days.
8. Material risks include: bleeding, cramping/pelvic pain, gastrointestinal symptoms (nausea/vomiting/diarrhea), headaches, fever or chills, and pelvic/lower genital infection.
9. Special risks include need for urgent surgical intervention (for heavy bleeding or retained products). Risk of mortality is about 0.3 in 100 000, usually from infection or undiagnosed ectopic pregnancy. The mortality risk is similar for SA, and lower than for a term pregnancy.⁸⁷

Medical Evaluation

Establishing pregnancy

A positive office-based urine beta human chorionic gonadotropin (β hCG) test is sufficiently sensitive to establish a pregnancy.

Determination of the gestational age

Upon diagnosis of pregnancy, assessment is needed to confirm that the pregnancy location and gestational age (GA) fall within limits for MA. Although overestimation of the GA is of limited consequence (gestation is earlier than expected), underestimation could result in women receiving a treatment when it may be inappropriate for MA.

Medical history. Among women seeking first-trimester abortion who are reasonably certain of their LMP, GA correlates closely to ultrasound.^{88–90} In a prospective study of 4484 women seeking medical abortion, use of LMP alone would have resulted in 2.4% of women receiving a MA beyond the approved GA.⁹¹ Older studies suggest slightly higher rates of underestimation.^{88,89}

Gynecological examination. Clinical examination alone has been shown to be accurate within 2 weeks of ultrasound determination of GA in the first trimester, but precision varies with provider experience, and the presence of obesity and fibroids.^{92,93} A prospective study showed that pelvic examination by an experienced provider accurately determined that pregnancies were within the 9-week eligibility window in 98.4% of women.⁹¹ In another multicentre US study, clinicians underestimated GA as less than 63 days in only 1% of patients and felt no need for ultrasound in the majority of cases.⁹⁴

Ultrasound. Ultrasound is considered the criterion standard, confirming pregnancy location and gestational

age^{95,96}; however, a systematic review failed to find direct evidence that routine use of ultrasound improved safety or efficacy compared with other diagnostic methods.⁹⁷

In many countries, ultrasound is not used routinely for MA, but rather only in cases of uncertainty about GA based on clinical assessment and LMP, or when there are symptoms of bleeding or pain. In France this practice has resulted in use of ultrasound in approximately 30% of abortions.⁹⁶ The Canadian monograph for MIFE/MISO states that ultrasound shall be performed before MA.⁹⁸

A transvaginal ultrasound can visualize a gestational sac by 32 to 33 days from LMP.^{96,99} The presence of a double-layer rounded eccentric collection of intrauterine fluid (decidual sign) is most likely a gestational sac.^{100–102} In general, the gestational sac is identified at ultrasound when β hCG level is above 1000 IU/L.⁹⁹ The appearance of a yolk sac inside the gestational sac occurs between 35 and 42 days from LMP. The yolk sac is identified at ultrasound when β hCG levels are between 7 200 and 10 800 IU/L.⁹⁹ Detection of a fetal pole and measurement of a crown-rump length (CRL) occur between 40 and 49 days.¹⁰³ The relevant measurements of CRL are 3.4 mm at 42 days, 8.5 mm at 49 days, 15 mm at 56 days, 22.4 mm at 63 days, and 30.1 mm at 70 days.¹⁰³

β hCG determination. β hCG levels rise linearly during the first 6 weeks of pregnancy—the high variability thereafter limits the utility of β hCG for dating. When the β hCG is < 5000 IU/L, the pregnancy is unlikely to be more than 6 weeks.⁹⁶ A study of 623 women receiving medical abortions found that a β hCG value of less than 23 745 IU/L had a sensitivity of 94% and specificity of 91% for detecting pregnancies < 42 days.¹⁰⁴

Ectopic pregnancy and pregnancy of unknown location

The risk of ectopic pregnancy (EP) in the general population is about 1%–2%.^{78,105} In abortion clinics, the rate of EP is consistently lower than baseline population rates.^{106,107} A 2009–2010 review of 233 805 MAs performed at Planned Parenthood Federation of America (PPFA) clinics in the United States showed that the rate of EP was 0.7 per 10 000 MAs (0.007%).¹⁰⁸ There was one death in this cohort resulting from an undiagnosed EP.¹⁰⁸

The Society of Family Planning (SFP),⁷⁵ the American College of Obstetricians and Gynecologists (ACOG),¹⁰⁹ and the National Abortion Federation (NAF)^{110,111} consider both confirmed or suspected EP to be contraindications to MA. It is recommended that women with significant medical risk factors (Table 4),¹¹² signs, or symptoms of EP should have a pretreatment ultrasound.

Table 4. Risk factors of ectopic pregnancy

History	Clinical symptoms
Previous ectopic pregnancy	Abdominal pain
Tubal surgery	Vaginal bleeding
Pregnancy conceived with assisted reproduction techniques	
Tubal ligation	
IUD in place	
History of salpingitis or pelvic inflammatory disease	

IUD: intrauterine device.

Adapted from Barnhart K, van Mello NM, Bourne T, Kirk E, Van Calster B, Bottomley C, et al. Pregnancy of unknown location: a consensus statement of nomenclature, definitions, and outcome. *Fertil Steril* 2011;95:857–66.¹¹²

Ultrasound is diagnostic of EP when an *extrauterine* gestational sac with a yolk sac or embryo is seen, whereas the diagnosis of an intrauterine pregnancy is usually considered definitive only when a yolk sac or embryo is identified within an *intrauterine* gestational sac.¹¹² The commonly used ultrasonographic features of an empty uterus, adnexal mass, and pseudogestational sac have poor sensitivity for identifying a tubal pregnancy.¹¹³ If no IUP and no EP is visualized by transvaginal ultrasound in a woman with a positive pregnancy test, the situation is classified as a pregnancy of unknown location (PUL).¹¹² PULs represent either failing intrauterine pregnancies, EP, or intrauterine pregnancies too early to be visualized using transvaginal ultrasound.¹¹⁴ Women requesting MA who are certain of their LMP may not require an ultrasound. In this case, they may also be considered as presenting with PUL.

All women with a PUL must be informed of the options for evaluation and management. The symptoms and dangers associated with EP, and a plan for when and how to seek emergency medical attention must be reviewed and documented. Failure to identify a definite intrauterine pregnancy should not delay abortion care at early gestation. Management of PUL is discussed in greater detail in the MA procedures section.

EVIDENCE-BASED MEDICAL ABORTION REGIMENS

There are many different medications and regimens that are safe and effective for medical abortion. The approved MIFE/MISO regimen also differs from country to country. In this section, MIFE/MISO and other evidence-based regimens are discussed. Although it is not possible to list every studied protocol, recommended regimens are summarized in [Tables 5](#) and [6](#). Detailed pharmacologic

information about the medications used for medical abortion is provided in a concurrent review article.¹¹⁵

Mifepristone/Misoprostol

In Canada, the approved MIFE/MISO combination product consists of 200 mg of mifepristone oral and 800 µg of misoprostol, buccal, taken 24 to 48 hours after mifepristone administration (MIFE200/MISO800*).

Indications

MIFE200/MISO800 is indicated for pregnancy termination up to 49 days.⁹⁸ There is no absolute lower gestational age limit, and there is robust data supporting its use as an effective regimen up to 70 days.^{9,116–118}

Contraindications

There are a number of conditions for which MIFE200/MISO800 is contraindicated.⁹⁸ In some circumstances, relative contraindications may permit use with precautionary advice.¹¹⁹

Absolute contraindications and rationale:

- Ectopic pregnancy*: MIFE/MISO regimens are not an appropriate treatment for EP, and the consequence of a missed diagnosis could be life-threatening.¹¹⁹
- Chronic adrenal failure*: MIFE is a potent anti-glucocorticoid and may potentially impair the action of cortisol replacement therapy in women with adrenal insufficiency.¹¹⁹
- Inherited porphyria*: MIFE has been shown to induce δ-aminolevulinic acid synthetase and mRNA at concentrations observed in human plasma after a single oral dose, indicating that the medication may pose risk in patients with known inherited porphyria.¹²⁰
- Uncontrolled asthma*: Although patients with mild asthma may respond to adjustment of corticosteroid therapy, the potent antiglucocorticoid activity of MIFE may compromise control of severe asthmatic attacks.¹²¹
- Known hypersensitivity to product ingredients*: Among 80 000 women receiving MIFE in the first 18 months of use in the United States, 6 women (0.008%) experienced a generalized urticarial reaction that resolved with oral diphenhydramine. Women who experience an allergic reaction should avoid further use.¹²²
- Ambivalence*: MA should only be initiated when a woman is certain of her decision.

* In this guideline, MIFE200/MISO800 combination refers specifically to the regimen of mifepristone 200 mg oral and misoprostol 800 µg, buccal, 24 to 48 hours following mifepristone administration. MIFE/MISO regimen refers to any kind of mifepristone and misoprostol regimen, where mifepristone may be at a dosage of 200 mg or more and misoprostol at a dosage of 400 µg or more, given orally, buccally, vaginally, or sublingually.

Relative Contraindications and rationale:

- a) *Unconfirmed gestational age*: When there is uncertainty regarding GA, ultrasound should be performed.⁸⁹
- b) *Intrauterine device in place*: Pregnancies with intrauterine device (IUD) in situ have a higher likelihood of being ectopic; therefore, EP must be rapidly excluded.¹¹⁹ If there is an IUP, the IUD should be removed before MA, if possible.
- c) *Concurrent long-term systemic corticosteroid therapy*: The effectiveness of long-term systemic corticosteroid therapy may be reduced for 3 to 4 days after MIFE administration. Steroid therapy should be adjusted.¹²¹
- d) *Haemorrhagic disorders or using concurrent anti-coagulation therapy*: Abortion and miscarriages routinely result in blood loss. In many studies, women with severe anaemia (< 9.5 mg/dL) were excluded. Precautionary measures may be appropriate.¹¹⁹

Effectiveness

For the process of approval in Canada, data from 3 open-label Phase 3 clinical trials (pivotal studies) confirmed that a protocol utilizing MIFE200/MISO800 in healthy women with an intrauterine pregnancy up to 49 days is effective (defined as a complete abortion without a surgical intervention).^{83,123,124} There were no clinically meaningful differences in pregnancy termination when results were stratified by age, ethnicity, or number of prior pregnancies (Table 5).⁹⁸

The use of MIFE/MISO in other regimens is summarized in Table 6.^{85,116–118,125–133} It is not exhaustive but lists appropriate evidence-based regimens that may be employed.

Table 5. Phase 3 pivotal studies for mifepristone 200 mg orally and misoprostol 800 µg buccal⁹⁸

	Study		
	1 (n = 146)	2 (n = 214)	3 (n = 551)
Termination of pregnancy without surgical procedure	95.2%	97.3%	98.0%
Surgical Evacuation	4.8%	2.7%	2.0%
Indication for surgery			
Persistent gestational sac	4.1%	0.9%	0.0%
Ongoing viable pregnancy	0.7%	0.9%	0.5%
Persistent heavy bleeding	–	0.9%	1.1%
Abdominal pain	–	–	0.4%
Patient lost to follow-up	6	4	17

Table 6. Evidence-based mifepristone-containing MA regimens

Medication and dose	Gestational age	Effectiveness
Mifepristone 200 mg oral/ misoprostol 800 µg buccal or vaginal	≤ 49 days	95.5%–97% ^{125–129}
Mifepristone 200 mg oral/ misoprostol 800 µg buccal, vaginal, or sublingual	≤ 63 days	94.2%–99.8% ^{85,125–133}
Mifepristone 200 mg oral/ misoprostol 800 µg buccal	64–70 days	90%–95.9% ^{117,118}
Mifepristone 200 mg oral/ misoprostol 400 µg sublingual	64–70 days	94.8% ¹¹⁶

Administration

Day 1: Mifepristone. Once the woman has decided on MA and is deemed eligible, the physician obtains consent and prescribes MIFE200/MISO800. The pharmacist dispenses the drug to the physician directly.⁹⁸ The woman takes one MIFE 200 mg tablet orally and swallows it with water. The woman takes home the box with 4 MISO tablets.

Day 2–3: Misoprostol. Twenty-four to 48 hours after taking MIFE, the woman places 4 MISO tablets (800 µg total) between the cheeks and teeth and leaves them in place for 30 minutes, at which point she swallows any leftover fragments with water. Alternative routes of administration include sublingual (under the tongue for 20 minutes, then swallow with water), or vaginal (place tablets high in the vagina and lie down for 30 to 60 minutes).

Day 7–14: Follow-up. Follow-up must take place to verify that expulsion has been completed (discussed in post-abortion care, below). If abortion is considered complete, no other follow-up is required. Additional follow-up is arranged as indicated.

Qualification to Provide Medical Abortion

At the time of publication, physicians must be registered in order to prescribe MIFE200/MISO800, which requires completion of an accredited online training course.¹³⁴ It is advised that physicians who are not able to perform surgical management make arrangements with abortion facilities or specialists in order to facilitate management of treatment failures or adverse events.

Prescribing practices differ in other countries. In Nepal, nurse-administered MA was as successful as physician-administered MA.¹³⁵ In Australia, MIFE200/MISO800 is dispensed in pharmacies directly to women (by

prescription), which has the potential to significantly increase access to MA.¹³⁶

The requirement to dispense to physicians creates an access barrier, as neither telemedicine nor nursing stations can be used to dispense drugs. Access inequities may hopefully drive a change in the regulation to ensure access to rural and remote areas.

Additional Evidence-Based Medical Abortion Regimens

MIFE/MISO regimens

Effectiveness of MIFE/MISO regimens at higher GA and in special circumstances is well established in the literature (Tables 6 and 7).^{78,79,82–84,123,125–128,130,137–148}

Although effective, increasing GA is associated with decreasing completion rates.¹⁴⁹ In a retrospective study of 13 713 women who obtained MA with MIFE200/MISO800, the success rate and ongoing pregnancy rate were 93.9% and 2.1%, respectively, at 57 to 63 days LMP, while it was 92.6% and 3.1% for MA at 64 to 70 days LMP.¹¹⁶

A few studies have compared the efficacy of early SA and early MA.^{24,31,40,85,150,151} In a study of over 33 000 SAs and nearly 17 000 MAs using MIFE 200 mg and MISO 800 µg vaginally or buccally for GA ≤ 63 days, the ongoing pregnancy rate was slightly higher among women undergoing MA (0.3% vs. 0.1%; relative risk [RR] 2.2; P = 0.0001). The rate of aspiration for incomplete abortion was also higher in the MA cohort.¹⁵⁰

Dosage and administration. A 2011 Cochrane Review⁹ compared several regimens of MIFE and prostaglandins and reached the following conclusions:

- According to 9 randomized, controlled trials (RCTs), failure to achieve complete abortion was similar between higher (600 mg) versus lower dose of MIFE (50 mg) groups (RR 0.90; 95% CI 0.77–1.05).
- Four RCTs found no difference in failure rates between regimens containing 600 mg versus 200 mg of MIFE (RR 1.07; 95% CI 0.87–1.32).
- Higher doses of MISO were associated with fewer ongoing pregnancies.

- Oral was less effective than the vaginal route for MISO and was associated with more frequent side effects. Sublingual and buccal routes were similarly effective to vaginal administration, but had higher side effects.
- Two RCTs found that failure to achieve abortion was lower when MISO was administered 36 to 48 hours compared with ≤ 6 hours after MIFE (RR 0.39; 95% CI 0.24–0.65). Two other trials showed that administration of MISO 1 day after MIFE was superior to administration less than 6 hours (RR 0.65; 95% CI 0.46–0.92).

Based on these data, the MIFE200/MISO800 regimen is one of the most effective regimens for pregnancies up to 70 days and nears the effectiveness of SA.

Methotrexate/Misoprostol regimens

In the absence of MIFE, MTX/MISO regimens have been the most frequently prescribed regimen in Canada.⁶

Indications. In Canada, MTX/MISO may be considered in circumstances where MA is appropriate, for example, when a woman has contraindications to MIFE or when MIFE200/MISO800 is unavailable. MTX/MISO regimens are indicated up to 63 days.

Contraindications. Contraindications to MTX/MISO abortion regimens differ from MIFE/MISO regimens. They include women who:

- Have a confirmed or suspected ectopic pregnancy
- Have anemia with hemoglobin levels of less than 9.5g/dL
- Have an IUD in place
- Have inflammatory bowel disease
- Have an active liver or renal disease
- Have hemorrhagic disorders or using concurrent anti-coagulation therapy
- Have known hypersensitivity to MTX, MISO, or any of the excipients of these medications
- Are ambivalent on the decision to abort

In studies on MA with MTX/MISO, women with uncontrolled seizure disorders, use of folates, inadequate vascular access, and unwillingness to abstain from intercourse and alcohol until completion have also been excluded.

Table 7. Effectiveness of various mifepristone and prostaglandins regimens according to gestational age

Gestational age	Complete abortion rate	Rate of ongoing pregnancy
≤ 42 days	95.8%–98.8% ¹³⁷	0.6%–1.2% ¹³⁷
≤ 49 days	92%–99% ^{125–128,130,138–142}	0%–1.2% ^{126–128,138–142}
≤ 56 days	91.3%–98% ^{123,130,143–148}	0%–3% ^{123,130,143–148}
≤ 63 days	87%–98.2% ^{78,79,82–84,125,129,130,133,137}	0%–3.5% ^{78,79,82–84,125,129,130,133,137}

Clinical efficacy. MTX/MISO regimen is effective for termination of pregnancy. Table 8^{80,152–160} includes various regimens of MTX/MISO with complete abortion rate within 3 to 7 weeks after MTX.

One major difference between these MTX/MISO and MIFE/MISO regimens is the longer delay to obtain complete abortion. A Canadian randomized, controlled trial of 1042 women demonstrated completion by day 8 in 75.5% in the MTX/MISO group compared with 90.5% in the MIFE/MISO group, and the mean number of days to completion was 7.1 days and 3.3 days, respectively.¹⁴² In a large multicenter trial, 69.7%, 87.7%, and 91.7% using MTX/MISO completed their abortion by 14, 28, and 35 days, respectively.

Gravidity < 3 is a positive predictor of complete abortion and high serum βhCG at baseline is a negative predictor.³⁴ MTX/MISO is less effective as GA advances.

Dosage and administration. A 2011 Cochrane Review⁹ compared several regimens of MTX/MISO and reached the following conclusions:

- There was no difference regarding the failure rate between intramuscular versus oral methotrexate.
- Only 1 trial¹⁶¹ compared buccal versus vaginal administration of MISO after MTX, and it concluded that the vaginal route was more effective (RR 1.43; 95% CI 1.08–1.90).
- There was no difference in achieving complete abortion between MISO given on day 3, 4, or 5 post-MTX.

Based on these data, MTX 50 mg orally or intramuscularly followed by MISO 800 μg administered vaginally 3 to 5 days later, for pregnancies up to 63 days, is an efficient regimen for MA.¹⁴²

Table 8. Evidence-based non-mifepristone-containing medical abortion regimens

Medication	Gestational age	Effectiveness
Methotrexate 50 mg oral/ misoprostol 800 μg vaginal	≤ 56 days	81.7%–98% ^{152–155}
Methotrexate 50 mg oral or intramuscular/misoprostol 800 μg vaginal	≤ 63 days	89%–96% ^{80,156–159}
Misoprostol 800 μg sublingual every 3 hours	≤ 63 Days	84% ¹⁶⁰
Misoprostol 800 μg vaginal every 3 hours	≤ 63 days	85% ¹⁶⁰
Misoprostol 800 μg sublingual every 12 hours	≤ 63 days	78% ¹⁶⁰
Misoprostol 800 μg vaginal every 12 hours	≤ 63 days	83% ¹⁶⁰

Misoprostol-only Regimens

MISO alone regimens have been used for MA in Canada.⁶ These usually require repeated doses and are not as effective as other regimens.

Indications. MISO regimens are effective up to 63 days.^{75,109,111} Women with contraindications to MIFE and MTX who desire MA may wish to consider MISO regimens.

Contraindications. Contraindications to MISO regimens differ slightly from other drug combinations. They include women who:

- Have a confirmed or suspected ectopic pregnancy
- Have anemia with hemoglobin levels of less than 9.5g/dL
- Have an IUD in place
- Have haemorrhagic disorders or using concurrent anticoagulation therapy
- Have known hypersensitivity to MISO or any of the excipients of the medication
- Are ambivalent on the decision to abort

In studies on MA with MISO, women with uncontrolled seizure disorders, evidence of uterine infection, prior uterine bleeding, hypertension, cardiovascular or cerebrovascular disease, inadequate venous access, and unwillingness to abstain from intercourse and alcohol until completion have also been excluded.

Clinical efficacy. Table 8 includes a few regimens of MISO with complete abortion rate at 2-week follow-up. Other protocols with MISO vaginal every 8 hours¹⁶² or 24 hours^{162,163} with follow-up 3 weeks after the first dose have shown effectiveness of 90.5% and 89.4%, respectively.

Success rates of MA with MISO increase with increasing number of doses and with sufficient time to assess completion of the abortion.^{164–166} For example, in one study, the success rate at one week was 87.1% with 1 dose of vaginal MISO 800 μg and 92% at 2 weeks after taking a second dose of vaginal MISO 800 μg.¹⁶⁴

Dosage and administration. Based on previous data, MISO 800 μg every 3 to 24 hours intravaginally or sublingually for pregnancies up to 63 days, is an appropriate regimen for MA although less efficient than other regimens with mifepristone or MTX.^{161–163}

PROVIDING MEDICAL ABORTION

First Visit for Medical Abortion

Once a woman has elected for MA, medical evaluation to determine suitability for the procedure is needed.

Clinical evaluation

A medical history must be taken to assess GA, to assist in regimen selection, exclude contraindications, identify additional precautions, and to determine appropriateness for aborting at home. This also provides a baseline for follow-up, assessment for contraception, and determines whether additional tests are indicated.

Baseline clinical assessment

Baseline vital signs should be verified. Pelvic examination should be performed as directed by history.

Gestational age determination

GA determination is discussed in Section 2. The MIFE200/MISO800 monograph states that ultrasound is required. Training in limited sonography for abortion care can be obtained; clinicians not trained in such skills should rely on appropriately trained colleagues.

Ultrasound

If performed, women should be offered the opportunity to view their ultrasound if they think it will aid in their decision-making or experience. Several studies have shown that viewing the ultrasound does not alter decision of the large majority of women who are certain that abortion is the right decision.^{167–169} However, in a small proportion of women with medium to low decision certainty, it may contribute to continue the pregnancy.¹⁶⁸

Molar pregnancy. Although ultrasound is useful in the detection of molar pregnancy, only 35% to 40% are diagnosed by ultrasound before 14 weeks.¹⁷⁰ Ultrasound findings suspicious for molar pregnancy require further workup and/or consultation. In these cases, surgical evacuation (with consideration for referral), histologic review, and follow-up of β hCG levels is essential. Medical evacuation is not appropriate, owing to lack of precision of diagnosis, and higher subsequent use of chemotherapy.¹⁷¹

Multiple pregnancies. The presence of multiples should be communicated to the woman (if she is agreeable to obtaining information about the pregnancy), as it may alter her decision regarding termination. In a study of 24 twin gestations compared with 2184 singleton pregnancies managed with MIFE200/MISO800 combination, treatment success was slightly lower than for singletons (91% vs. 97%), but the difference was not statistically significant.¹⁷² Therefore, multiple pregnancies is not a contraindication to MA.

Missed and incomplete abortions. Reported frequencies of spontaneous abortion are highly variable, with larger estimates between 8% and 20%.¹⁷³ Table 9^{101,174} provides the criteria for pregnancy failure.

Table 9. Criteria for pregnancy failure*

Crown-rump length (CRL) \geq 7 mm and no heartbeat
Mean sac diameter (MSD) \geq 25 mm and no embryo
Absence of embryo with heartbeat \geq 2 weeks after a scan that showed a gestational sac without a yolk sac
Absence of embryo with heartbeat \geq 11 days after a scan that showed a gestational sac with a yolk sac

*Criteria from the Society of Radiologists in Ultrasound Multispecialty Consensus Conference on Early First Trimester Diagnosis of Miscarriage and Exclusion of a Viable Intrauterine Pregnancy, October 2012.^{101,174}

Diagnosis of missed abortion should be disclosed to the woman and expectant management, a MISO regimen, or curettage should be considered. There is limited evidence for the use of mifepristone in the setting of missed abortion.¹⁷⁵

Laboratory investigations

Baseline hemoglobin should be performed as indicated by clinical history, or to establish a baseline value.¹⁷⁶ Complete blood count, liver, and renal function tests should be considered for women receiving MTX.¹⁷⁷

Rh status. Fetal red blood cells express Rh antigen starting at 52 days from LMP.¹⁷⁸ There is sufficient maternal-fetal transfusion during surgical abortion at 63 days to cause alloimmunization.¹⁷⁸ Almost 10% of women undergoing elective surgical abortion at 5 to 6 weeks have a positive Kleihauer-Betke test, but this does not clearly correlate to alloimmunization.¹⁷⁸

There is limited evidence for use of Rh immune globulin below 49 days,¹⁷⁸ and in many countries, Rh testing starts at 8 weeks gestation. However, Rh alloimmunization may jeopardize the health of a subsequent pregnancy, and its prevention is safe and readily available. Therefore, routine Rh testing and administration of immune globulin is advised. In order to provide informed choice, women should be advised that the data on Rh administration is limited.

STI screening

Chlamydia, gonorrhea, and bacterial vaginosis are associated with increased rates of endometritis following surgical abortion.^{179,180} For MA, either screening (urine or cervicovaginal swabs) and treatment if positive; or routine antibiotic prophylaxis for chlamydia and gonorrhea are acceptable to mitigate this risk.^{181–184}

IUD removal

If the pregnancy has resulted from a failed IUD, the risk of EP is high, and it must be urgently excluded (with ultrasound and referral if indicated). If the pregnancy is intrauterine and IUD strings are visible, remove the device before providing MA.

Medical Abortion in Setting of Pregnancy of Unknown Location

Several studies discuss the management of PUL among women seeking MA. If an ultrasound is highly suggestive but not diagnostic of IUP, clinicians should not delay initiation of the MA while waiting for a confirmatory ultrasound.¹¹¹ In these situations, EP should be ruled out and PUL protocol be followed.¹⁷⁷

Published evidence on MA in women with PUL is minimal.^{185–187} Two small studies have examined outcomes of MIFE/MISO regimens in women with no gestational sac on transvaginal ultrasound.^{185,186} Both studies used serum β hCG follow-up and considered a decrease of 50% by the first follow-up visit (3–19 days) to exclude an ongoing pregnancy or EP. Success rates were 91% to 93%, lower than in pivotal studies presented to Health Canada.^{185,186} In these studies, all EPs were detected. However, in a case series of 1309 MAs, 1 ectopic was missed using a similar follow-up protocol.¹⁸⁸

Based on available data, the following represents a safe approach^{185–187,189,190}:

- ***If risk factors or clinical features of EP are present and no intrauterine gestational sac*** is visualized, whatever the level of β hCG, further investigation is required to rule out EP before MA.
- ***If the serum β hCG level is > 2000 IU/L and no intrauterine gestational sac*** is visualized on ultrasound, further investigation is required before MA, regardless of risk factors and symptoms.¹¹⁰ Experienced clinicians who can perform adequate investigations and follow-up may, along with a consulting gynaecologist, develop a local protocol or referral agreement using a higher threshold.
- ***In the absence of risk factors/clinical symptoms and no gestational sac, if the β hCG is \leq 2000 IU/L***, it is reasonable to proceed with MA. However, women should be informed of the risks and symptoms of EP and where to consult in case of emergency. Follow-up β hCG within 7 days is required. A decrease of 50% at 24 hours post-MISO or 80% at 7 days post-MIFE is expected; otherwise, EP should be ruled out.
- ***In the absence of risk factors/clinical symptoms, when a likely gestational sac is present without a yolk sac or fetal pole***, it is reasonable to proceed to MA. However, women should be informed of the risks and symptoms of EP and where to consult in case of emergency. Follow-up β hCG in 7 days post-MIFE is required. An 80% decrease is expected; otherwise, EP should definitively be ruled out.

Some clinicians prefer early follow-up in women with PUL. MIFE200 can be given on day 1, MISO800 on day 2, and β hCG be repeated on day 3. A drop of more than 50% in the β hCG level is highly indicative of a complete abortion.¹⁸⁵

MTX can be used for MA as well as for treatment of EP, and some providers have suggested it as alternative regimen for women with no gestational sac on ultrasound and no evidence of EP, as this regimen could manage both.^{186,187} Evidence suggests that MTX as a single dose intramuscular (50 mg/m²) is effective in terminating an EP.¹⁹¹ Two or more doses of intramuscular MTX have been evaluated for use on day 1 and 4, planning a second dose if the β hCG does not decrease; 87% of women were successfully treated without surgical intervention with this approach.¹⁹²

For very early pregnancies, early surgical abortion is also a viable alternative, as it may provide trophoblastic tissue, providing exclusion of EP. Special protocols for early surgical abortion exist to reduce the risk of EP and ongoing pregnancy.¹⁵¹

Antibiotic Prophylaxis

The role of universal antibiotic prophylaxis for SA is well established.^{193,194} Evidence of its use for MA is limited. Although the frequency of infections after MA is very low (0.02% in a 2009–2010 PPFA review of 233 805 MA¹⁰⁸), reports of fatal infections following MA^{195–197} warrants careful examination of this question.

In 2006, following case reports of clostridial toxic shock in women undergoing MA, PPFA recommended that MISO be administered buccally instead of vaginally, and centres were required to use 1 of either a) routine antibiotic coverage (oral doxycycline 100 mg twice a day for 7 days, starting the same day as MIFE administration), or b) universal testing for chlamydia (and for gonorrhoea when considered appropriate), with treatment dependent on test results (oral doxycycline 100 mg twice a day for 7 days for chlamydia and ceftriaxone 125 mg intramuscular in a single dose for gonorrhoea).^{181,195–197} In the 2 to 3 years after this decision, a 73% decline in the rate of serious infections, from 0.93/1000 to 0.25/1000 ($P < 0.001$), was observed; a further decrease to 0.19/1000 ($P = 0.003$) occurred when universal routine provision of antibiotics was implemented.¹⁸¹ Before 2006, there had been 3 fatal cases related to Clostridium species; after 2006, no deaths were reported.¹⁸²

Because both interventions were instituted at the same time and because of a possible period effect bias, the extent to which each intervention contributed to the drop in serious infection is unclear.^{181,182,195} Additionally, 2500 women need to be treated to prevent 1 serious infection,¹⁹⁸

adherence to doxycycline is poor (28.3%), and it is associated with nausea and vomiting.¹⁹⁹ Therefore, routine prophylactic antibiotics are not necessarily superior to screen-and-treat approach.

Neither NAF,¹¹¹ ACOG,¹⁰⁹ SFP,⁷⁵ nor the WHO⁵⁶ recommends routine prophylactic antibiotic use after MA. When possible, screen-and-treat is preferred. Women should always be advised to monitor symptoms and signs of infection in the week following MA and consult her provider or emergency care in case of concerns.

Side Effect Management

MA is associated with several side effects related to the drugs used to initiate the abortion and also to the process itself. Proactive counselling will help alleviate fears about MA and known side effects.

Bleeding

Women should expect bleeding to start a few hours after administration of MISO, with bleeding heavier than regular menses and clots for 2 to 4 hours. They may pass tissue but not an obvious fetus if less than 56 days. Mild bleeding can be managed expectantly, with further investigation being directed by history or signs. The risk of blood transfusion following MA is around 0.1%.¹³² The risk of aspiration due to bleeding ranges from 0.65% to 2.49% and increases with GA.¹⁷⁶ In the 3 pivotal trials for the approved regimen, there were no treatment-emergent adverse events related to bleeding out of 898 women.^{83,123,124}

An understandable reference for women is that too much bleeding would be if she is soaking 2 maxi pads per hour for more than 2 consecutive hours, or if she has symptoms of dizziness, light-headedness, or racing heart rate.²⁰⁰

Pain

Some cramping and pain is to be expected before and at the time of expulsion. More advanced gestations and higher doses of MISO are associated with more pain.²⁰¹ Older women and women with previous deliveries report less pain.²⁰¹ In most instances, non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen 200–400 mg every 8 hours or naproxen 225–500 mg every 12 hours can be used to lessen these symptoms. Evidence suggests that ibuprofen is superior to acetaminophen,²⁰² and that prophylactic dosing is not superior to as-needed dosing.^{202,203} NSAIDs do not interact or interfere with MISO.²⁰⁴

Mild opioid analgesics (e.g., codeine or oxycodone) can be helpful for significant cramping or severe pain, and women can be offered a prescription for this to take as needed.²⁰¹

Severe pain should be evaluated to rule out infection and retained products.

Prostaglandin effects

Prostaglandin effects include nausea (experienced by about 30%), vomiting (21%), diarrhea (58%), dizziness (13%), headache (13%), and thermoregulatory symptoms (chills and fever; 45%).^{83,125,130,142,205} These effects are similar between buccal and sublingual route (chills may be more common with sublingual).²⁰⁶ Gastrointestinal symptoms are less common when given vaginally.^{9,207} Nausea can be treated with dimenhydrinate, ondansetron, or dicyclanil. Diarrhea is usually self-limited and can be managed with over-the-counter medications in most cases. Thermoregulatory symptoms are often self-limited. Women worried about infection should contact their health care provider or on-call provider for advice. Fever is not a reliable sign of severe infection.

POST-ABORTION CARE

Follow-up After Medical Abortion

The purpose of follow-up is to confirm termination of the pregnancy and to manage complications.

Women undergoing MA should have follow-up 7 to 14 days after administration of MIFE. This can be done by clinical examination, ultrasound, or β hCG measurement.

The most common method of follow-up in North America is an in-clinic follow-up visit, during which a woman will have an ultrasound. However, telemedicine visits, along with serum or urine β hCG and symptom checklists are also employed.^{16,144,208,209} In a recent Canadian study where women were given the choice between in-clinic and telephone follow-up with serum β hCG, 67% chose remote follow-up.²¹⁰ No-show rates for remote (28%) and in-clinic (23%) follow-up was statistically similar.²¹⁰ Follow-up plans and appointment information should be documented in the clinical chart.

Phone coverage

The NAF requires that a 24-hour telephone coverage be provided to women undergoing MA.⁵⁶ A 3-month study of patient-initiated calls after MA found that, among 100 calls from 671 women who had undergone MA (14.9%), 33% were considered nonpreventable.²¹¹ In 16 cases (16%), the clinician changed care (e.g., prescribed antibiotics). Most preventable calls (e.g., “not enough bleeding” or “when should I take the misoprostol”), could be mitigated by written patient education. Every woman must receive detailed information about how to recognize serious complications and access emergency medical care either directly or by telephone.⁵⁶

Emergency contact details for women lost to follow-up

Women should be offered a variety of options for contact (e.g., phone, email, contacting a friend), and emergency contact information should be obtained when possible. Steps should be taken not to contact an abusive partner or uninformed parent if requested by the woman.

Confirmation of Completion of the Medical Abortion

Symptom checklists, gynecological examination, ultrasound, and serum and urine β hCG measurements, combined with in-clinic, telephone or video visits, are used to confirm completion of MA.

Clinical history

Women's and clinicians' assessments of successful expulsion based on medical history are highly predictive of complete abortion (sensitivity 99.1%, specificity 45.5%).^{212,213} Ninety-five of 111 women who self-assessed expulsion of the pregnancy were correct (sensitivity 85.6%; CI 77.3%–91.3%), but 4% were judged to have an ongoing pregnancy upon clinician assessment.²¹⁴ Minimal or no bleeding after MISO and continuing pregnancy symptoms are suggestive of an ongoing pregnancy.²¹² There is insufficient evidence to conclude that history alone is adequate to identify MA failure.^{215,216}

Use of a structured symptom checklist combined with a urine pregnancy test is effective at diagnosing ongoing pregnancies, but may result in more ultrasounds.^{215,217} Symptom checklists were not found to confer benefit over semiquantitative urine tests alone.²¹⁸

Gynecological examination

Gynecological examination may be combined with history to confirm completion.⁹⁵ However, many centres favor other methods of assessment and conduct examination only when indicated.^{217,219}

Ultrasound

Ultrasound provides definitive evidence of MA completion; however, there is no evidence that routine ultrasound is superior to other follow-up modalities. Ultrasound is helpful when the outcome is uncertain or where there are symptoms such as unexpected pain, prolonged, heavy bleeding, or inadequate bleeding. When ultrasound is used, retained debris in the uterus is an expected finding and should not prompt treatment in the absence of symptoms.^{220,221}

 β hCG determination

Serial serum β hCG determination can accurately predict a termination of the pregnancy.²²² Serum β CG levels fall more than 50% within 24 hours of pregnancy expulsion but may remain detectable at low levels for 4 to 6

weeks.^{220,223–226} In an observational study of 217 women, a drop in serum β hCG of 80% from pre-treatment levels by day 8 to 16 accurately predicted successful expulsion in 98.5% of cases and had a sensitivity of 98.59% (95% CI 95.94%–99.71%) and specificity of 75% (95% CI 19.41%–99.37%).¹⁹⁰ Serial β hCG is more accurate than ultrasound at assessing completion, particularly when ultrasound did not definitively confirm an IUP.¹⁹⁰

The utility of urine β hCG tests to determine abortion outcome has been widely studied.^{16,144,208,219,227} None has been adequately powered to evaluate their ability to exclude continuing pregnancy, and false negatives are reported.^{16,144,218,228} When used 14 days after MIFE, although false positives are common, a negative test was highly correlated with a complete abortion (negative predictive value: 99%; 95% CI 96%–100%).²²⁸ A strategy using 7-day structured telephone follow-up combined with home testing with a low-sensitivity urine β hCG test at 1 month successfully identified all continuing pregnancies.²²⁹ A recent RCT determined that self-assessment with a semiquantitative test was noninferior to routine assessment to determine completion; however, 3 ongoing pregnancies were missed.¹⁶ In another study in Vietnam, 1 of 14 ongoing pregnancies was missed.²¹⁸

Complications of Medical Abortion**Retained products of conception**

Retained products of conception (RPOCs) are more common after MA than SA.^{28,230} Rates vary according to the regimen used and GA.^{132,230} On average, approximately 3% to 5% of women having MIFE-based MA have a subsequent aspiration.^{132,176} Symptoms include unexpected heavy or prolonged bleeding and cramping, or, in the case of a nonexpelled pregnancy, failure to have expected bleeding. In the absence of ongoing pregnancy (cardiac activity), management can be expectant, medical (MISO), or surgical (aspiration).

When ultrasound is performed, findings of a thickened endometrium, hyperechoic tissue, and color Doppler flow are common, and do not necessarily require intervention.^{221,231–233} In a report involving 2208 women, endometrial thickness did not predict the subsequent need for a curettage.²²¹ If the gestational sac has been expelled, women with additional ultrasound findings should be managed expectantly, unless symptoms arise.²²¹

Women with persistent gestational sac 1 week after treatment have several options.^{83,234} As pregnancy symptoms are diminished, most women are comfortable to wait for bleeding and cramping. Even after 14 days, expulsion most

often occurs without intervention.^{200,233} In an analysis of two RCTs, 69% of those who received MISO for a persistent gestational sac expelled the pregnancy.^{200,233} Elective aspiration should be offered, as some will not want to wait. Urgent aspiration is indicated for heavy uncontrolled bleeding or RPOCs associated with endometritis.

Ongoing pregnancy

Ongoing pregnancy (persistent cardiac activity) after MA is uncommon.^{176,235} Of 14 women with ongoing pregnancy who received a second dose of vaginal MISO 800 µg at first follow-up, 5 had continued cardiac activity after 1 more week, 4 had a non-viable pregnancy, and 5 had passed the pregnancy.²³⁴ Women with ongoing pregnancy at first follow-up should be offered aspiration or MISO, with aspiration if cardiac activity is present 1 week later (14–21 days after MIFE).

Post-abortion infection

The exact incidence rate of post-abortion infection is difficult to evaluate.²³⁶ The frequency of diagnosed and/or treated infection in a 2004 systematic review was 0.92%, (n = 46 421).²³⁶ The most common infections were endometritis (49%) and undefined genital tract infection (37%), and all were treated without sequelae. The rates of infection vary by regimen: 1.33% for MIFE and vaginal MISO, 0.18% for MIFE and oral MISO, 0.13% for MTX/vaginal MISO, and 0.45% for vaginal MISO alone. A retrospective study of PPFA reported rates for serious infection in 2009–2010 (infection requiring treatment with intravenous antibiotics either in an emergency department of inpatient unit, or cases in which sepsis or death caused by infection was documented) of 0.016%.¹⁰⁸ The usual symptoms and signs of pelvic infection are listed in Table 10.^{56,61,237}

Infections are usually polymicrobial.²³⁸ Because there is no introduction of instruments in the uterus, the pathogenesis of infections after MA is still unclear, and many theories have been suggested. Retained products may form a nidus for infection.²³⁸

Table 10. Common signs and symptoms suggestive of infection^{56,61,75,237}

Abdominal or pelvic pain
Foul-smelling vaginal or cervical discharge
Prolonged vaginal bleeding or spotting
Fever or chills (more than 24 hours after misoprostol)
Uterine or adnexal tenderness
Elevated white blood cell count

Treatment should be individualized and usually consists of broad-spectrum therapy.^{61,237} Oral antibiotics can be used in mild cases.²³⁷ If the infection is severe or not responding to oral antibiotics, the woman should be hospitalized for treatment.²³⁷ Treatment regimens for pelvic inflammatory disease can be found in the Canadian Guidelines on Sexually Transmitted Diseases.²³⁹ In women with significant RPOCs, aspiration may be necessary once antibiotic therapy has been initiated.^{56,237}

Toxic shock syndrome

Toxic shock syndrome associated with *clostridium* and Group A *streptococcus* have been reported following MA.^{197,240-245} However, these are not unique to abortion: toxic shock and death from clostridial infections have occurred following spontaneous miscarriage, vaginal delivery, cervical diagnostic excisional procedures, and Caesarean section.⁷⁵

Clostridia are gram negative, anaerobic, spore-forming bacteria commonly found in soil and the digestive tract of humans and other animals.¹⁹⁷ They are isolated from the vagina in 4% to 18% of normal healthy women.^{196,197,240} Clostridial toxic shock is mediated by toxins that cause severe systematic capillary leak, leading to decreased vascular resistance and cardiovascular collapse.²⁴⁶

Vigilance in considering clostridial infections is required when patients present with vague symptoms (Table 11).^{61,75,197,240,242,247,248} A clinical syndrome is recognized as *Clostridium sordellii*-like associated toxic shock (CSTS) or *Clostridium sordellii*-associated toxic shock (CATS).^{247,248} The majority of these infections are fulminant and rapidly progress to shock.^{240,248} Standard antibiotic therapy is not sufficient.^{197,242,249} The treatment consists of supportive care; empiric antibiotic treatment covering clostridial species (e.g. β-lactams, clindamycin, tetracyclines) and other organisms known to cause toxic

Table 11. Signs and symptoms suggestive of clostridial infection/toxic shock^{61,75,197,247,248}

General malaise with nausea, vomiting, and diarrhea
Absence of fever (or mild fever)
Minimal abdominal pain
Weakness
Flu-like symptoms
Tachycardia
Hypotension
Edema
High white blood cell count
High hemoglobin level (hemoconcentration)

shock; and surgical debridement, including possible hysterectomy.^{242,246–248}

Future Fertility and Pregnancy Risks

Despite the limited evidence, data about MA and reproductive outcomes should be reassuring to women undergoing MA. Fertility is rapidly restored following MA. In 1 study, in fact, unintended pregnancy was common within the first year following MA.²⁵⁰

Few studies have looked at the pregnancy outcomes after MA. Women having had 1 MA had a lower risk of preterm delivery compared with women without a previous abortion (0.77; 95% CI 0.61–0.98). There were no significant differences in the rate of low birth weight and mean length of pregnancy between these two groups.²⁵¹ There was also no difference between MA and SA for any of the outcomes.²⁵² A database study in Scotland did not demonstrate an increased risk of preterm birth in women with a history of MA.²⁵³

Contraception after Medical Abortion

Because return to fertility is rapid (20.6 ± 5.1 [range 8–36] days), a contraceptive plan should be initiated at the first visit.²⁵⁴ If contraception is delayed, women are less likely to use effective contraception and more likely to have a repeat unintended pregnancy.²⁵⁵ In the absence of other contraindications, all hormonal contraceptive methods are safe to use.^{256,257}

Hormonal contraception

Combined hormonal contraception. Two randomized, placebo-controlled trials of combined oral contraceptives (COC) initiation after MA with MIFE^{258,259} found that there were no differences completion rates, bleeding, or adverse events when COCs were initiated the first day after MISO. There was a small decline in hemoglobin in the COC group at day 15, which returned to normal by day 43.^{258,259}

One small study assessed vaginal contraceptive ring insertion within 1 week after MA in 11 women, with no serious adverse effects reported.²⁶⁰

Progestin-only contraception. There is theoretical concern that the efficacy of progestin-only contraception is reduced following use of mifepristone.^{255,261} To date, there are no studies demonstrating reduced effect of progestin-only pills (POPs) when used after MA. A recent study on ulipristal acetate (UPA) emergency contraception (a selective progesterone receptor modulator with less antiprogestogenic effect than mifepristone) and quick start of POP found impaired ability of UPA to delay ovulation.²⁶²

A pilot study of 20 patients who received depot medroxyprogesterone acetate (DMPA) on the day of MIFE administration found MA failure in 3 subjects (18%) and low rates of DMPA continuation at 3 months (47%) and 1 year (15.7%).²⁶³ The authors concluded that early injection of DMPA may influence the efficacy of MA and required further study.²⁶³ A recent study found that the insertion of etonogestrel implants at the time of taking mifepristone compared with after MA did not appreciably impact MA failure risk or repeat abortion rate, and it enhanced patient satisfaction.²⁶⁴

More studies are needed to determine the ideal time to start progestin-only contraceptive methods following MA with MIFE. It is preferred to start progestin-only methods once MISO has been taken.

Barrier methods and spermicide

Condoms and spermicide can be used immediately after abortion as soon as intercourse resumes.²⁵⁵ There is no optimal timing for use of cervical cap or diaphragm following MA.

Intrauterine contraceptives

The optimal timing for IUC placement after MA has been studied in one observational study²⁶⁵ and two RCTs.^{266,267} In one study in which women were randomly selected to receive a copper IUD at either 1 or 4 to 6 weeks after MIFE, insertion rates were higher in the 1-week group, although rates of use at 6 months were not significantly different.²⁶⁷ There were no differences in the rates of expulsion, removal requests, or bleeding patterns.²⁶⁷ A second RCT comparing IUC insertion 5 to 9 days versus 3 to 4 weeks after MA found no difference in expulsion rates.²⁶⁶ A higher proportion of women in the delayed insertion group did not attend follow-up (11.5% vs. 1.5%; $P = 0.015$) and had unprotected intercourse before returning for insertion (41% vs. 16%; $P = 0.015$).²⁶⁶ In both studies, adverse events did not occur in either group. The risk of IUD expulsion after MA, although uncommon, appears to increase with increased endometrial thickness; however, it is not recommended to restrict IUD insertion based on ultrasound findings.²⁶⁸

Post-abortion Counselling

Women with an unintended pregnancy are at no higher risk of mental health problems if they have an abortion or delivery.^{269–271} There is no convincing evidence that abortion causes severe psychological outcomes.^{272,273} The evidence regarding mental health risks associated with multiple abortions is equivocal and can be explained by co-occurring risk factors.^{274–276}

Emotional responses to abortion are highly variable.²⁶⁹ Risk factors for emotional distress or negative reactions may be related to a number of factors, including maternal age, pressure in pregnancy decision-making or high decisional conflict, lack of perceived social support, low socioeconomic status, interpersonal violence, history of depression, moral discomfort with abortion, and existence of co-occurring stressors.²⁶⁹ Fear of judgment or disapproval may discourage women from disclosing distress.²⁶⁹

Clinicians can support women after MA by providing a nonjudgmental and disclosure-friendly environment, normalizing common reactions, exploring coping strategies and supports, identifying women who are not coping well, using validated depression screening tools when indicated, and facilitating referrals if further counselling is needed.^{269–272,274,276–279}

REFERENCES

- Borgatta L, Kapp N, Society of Family Planning. Clinical guidelines. Labor induction abortion in the second trimester. *Contraception* 2011;84:4–18.
- Norman WV. Induced abortion in Canada 1974-2005: trends over the first generation with legal access. *Contraception* 2012;85:185–91.
- Statistics Canada. Induced abortions in hospitals and clinics, by age group and area of residence of patient, Canada, provinces and territories, annual 1974-2006, CANSIM table 106-9034. 2009;. Available at: <http://www5.statcan.gc.ca/cansim/a26?lang=eng&cid=1069034>. Accessed on February 28, 2015.
- Statistics Canada. Data Quality in the Therapeutic Abortion Survey. 2007;. Available at: http://www23.statcan.gc.ca/imdb-bmdi/document/3209_D4_T2_V7-eng.pdf. Accessed on February 28, 2015.
- Canadian Institutes for Health Information. Induced abortions performed in Canada in 2013. 2015;. Available at: https://www.cihi.ca/en/quick-stats?field_type_of_quick_stats_tid=All&field_topic_tid=All&items_per_page=10&page=4. Accessed on April 13, 2016.
- Guilbert E, Hayden A, Jones H, O'Connell WK, Paul M, Lichtenberg ES, et al. First-trimester medical abortion practices in Canada: A National Survey. *J Obstet Gynaecol Can* 2015;37:474.
- Norman WV, Guilbert E, Okpaleke C, Lichtenberg ES, Paul M, O'Connell WK. Abortion services in Canada: Results of the 2012 national survey. *Contraception* 2014;90:300.
- Map of Mifepristone approvals. Gynuity Health Projects [Internet]. 2005. Available at: <http://gynuity.org/resources/info/map-of-mifepristone-approvals/>. Accessed on September 8, 2015.
- Kulier R, Kapp N, Gulmezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester abortion. *Cochrane Database Syst Rev* 2011;CD002855.
- Paul M, Slichtenberg S, Borgatta L, Grimes DA, Stubblefield PG, Creinin MD. Management of unintended and abnormal pregnancy: comprehensive abortion care. Chichester, West Sussex, United Kingdom: Wiley-Blackwell; 2009. p. 392.
- White K, Carroll E, Grossman D. Complications from first-trimester aspiration abortion: a systematic review of the literature. *Contraception* 2015;92:422–38.
- Dunn S, Cook R. Medical abortion in Canada: behind the times. *CMAJ* 2014;186:13–4.
- Gåsemyr K, (redaktør), Totlandsdal J, Mjaatvedt A, Seliussen I, Englund I, Ebbing M. Rapport om svangerskapsavbrudd for 2012. Nasjonalt folkehelseinstitutt, Abortregisteret, Bergen, 2013. Report No.: ISSN 1891-6392. Available from: http://www.fhi.no/eway/default.aspx?pid=239&trg=Content_6502&Main_6157=6246:0:25,5498&Content_6502=6259:106415:25,5498:0:6634:1::0:0. Accessed on September 15, 2015.
- Lokeland M, Iversen OE, Engeland A, Okland I, Bjorge L. Medical abortion with mifepristone and home administration of misoprostol up to 63 days' gestation. *Acta Obstet Gynecol Scand* 2014;93:647–53.
- Nisand I, Bettahar K, Investigators of the aMaYa Study. Medical management of unwanted pregnancy in France: modalities and outcomes. The aMaYa study. *Eur J Obstet Gynecol Reprod Biol* 2015;184:13–8.
- Oppegaard KS, Qvigstad E, Fiala C, Heikinheimo O, Benson L, Gemzell-Danielsson K. Clinical follow-up compared with self-assessment of outcome after medical abortion: a multicentre, non-inferiority, randomised, controlled trial. *Lancet* 2015;385:698–704.
- Pazol K, Creanga AA, Burley KD, Jamieson DJ. Abortion surveillance - United States, 2011. *MMWR Surveill Summ* 2014;63:1–41.
- Jones RK, Henshaw SK. Mifepristone for early medical abortion: experiences in France, Great Britain and Sweden. *Perspect Sex Reprod Health* 2002;34:154–61.
- Kaposy C. Improving abortion access in Canada. *Health Care Anal* 2010;18:17–34.
- Norman WV, Soon JA, Maughn N, Dressler J. Barriers to rural induced abortion services in Canada: findings of the British Columbia Abortion Providers Survey (BCAPS). *PLoS One* 2013;8:e67023.
- Sethna C, Doull M. Far from home? A pilot study tracking women's journeys to a Canadian abortion clinic. *J Obstet Gynaecol Can* 2007;29:640–7.
- Sethna C, Doull M. Spatial disparities and travel to freestanding abortion clinics in Canada. *Women's Studies International Forum* 2013;38:52–62.
- Bachelot A, Cludy L, Spira A. Conditions for choosing between drug-induced and surgical abortions. *Contraception* 1992;45:547–59.
- Henshaw RC, Naji SA, Russell IT, Templeton AA. Comparison of medical abortion with surgical vacuum aspiration: women's preferences and acceptability of treatment. *BMJ* 1993;307:714–7.
- Nhu-Ngoc NT, Winikoff B, Clark S, Ellertson C, Ngoc AK, Trong Hieu D, et al. Safety, efficacy and acceptability of mifepristone-misoprostol medical abortion in Vietnam. *Int J Fam Plann Perspect* 1999;25:10–4.
- Robson SC, Kelly T, Howel D, Deverill M, Hewison J, Lie ML, et al. Randomised preference trial of medical versus surgical termination of pregnancy less than 14 weeks' gestation (TOPS). *Health Technol Assess* 2009;13:1–124. iii–iv.
- Rodriguez MI, Seuc A, Kapp N, von Hertzen H, Huong NT, Wojdyla D, et al. Acceptability of misoprostol-only medical termination of pregnancy compared with vacuum aspiration: an international, multicentre trial. *BJOG* 2012;119:817–23.
- Rorbye C, Norgaard M, Nilas L. Medical versus surgical abortion efficacy, complications and leave of absence compared in a partly randomized study. *Contraception* 2004;70:393–9.
- Tang GW. A pilot study of acceptability of RU486 and ONO 802 in a Chinese population. *Contraception* 1991;44:523–32.
- Tang GW, Lau OW, Yip P. Further acceptability evaluation of RU486 and ONO 802 as abortifacient agents in a Chinese population. *Contraception* 1993;48:267–76.
- Winikoff B, Sivin I, Coyaji KJ, Cabezas E, Xiao B, Gu S, et al. Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone-misoprostol versus surgical abortion. *Am J Obstet Gynecol* 1997;176:431–7.
- Woldetsadik MA, Sendekie TY, White MT, Zegeye DT. Client preferences and acceptability for medical abortion and MVA as early pregnancy termination method in northwest Ethiopia. *Reprod Health* 2011;8:19.

33. Creinin MD, Park M. Acceptability of medical abortion with methotrexate and misoprostol. *Contraception* 1995;52:41–4.
34. Creinin MD, Vittinghoff E, Keder L, Darney PD, Tiller G. Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy. *Contraception* 1996;53:321–7.
35. Wiebe ER. Choosing between surgical abortions and medical abortions induced with methotrexate and misoprostol. *Contraception* 1997;55:67–71.
36. Winikoff B, Ellertson C, Elul B, Sivin I. Acceptability and feasibility of early pregnancy termination by mifepristone-misoprostol. Results of a large multicenter trial in the United States. *Mifepristone Clinical Trials Group. Arch Fam Med* 1998;7:360–6.
37. Creinin MD. Randomized comparison of efficacy, acceptability and cost of medical versus surgical abortion. *Contraception* 2000;62:117–24.
38. Honkanen H, von Hertzen H. Users' perspectives on medical abortion in Finland. *Contraception* 2002;65:419–23.
39. Winikoff B. Acceptability of medical abortion in early pregnancy. *Fam Plann Perspect* 1995;27:142–8. 185.
40. Jensen JT, Harvey SM, Beckman LJ. Acceptability of suction curettage and mifepristone abortion in the United States: a prospective comparison study. *Am J Obstet Gynecol* 2000;182:1292–9.
41. Jones HE, O'Connell WK, Lichtenberg ES, Paul M, Guilbert E, Norman WV. Abortion providers' resilience to anti-choice tactics in the United States and Canada. *Contraception* 2014;90:300.
42. American College of Obstetricians and Gynecologists. ACOG Committee opinion no. 554: reproductive and sexual coercion. *Obstet Gynecol* 2013;121:411.
43. Coker AL, Derrick C, Lumpkin JL, Aldrich TE, Oldendick R. Help-seeking for intimate partner violence and forced sex in South Carolina. *Am J Prev Med* 2000;19:316–20.
44. Davila YR, Brackley MH. Mexican and Mexican American women in a battered women's shelter: barriers to condom negotiation for HIV/AIDS prevention. *Issues Ment Health Nurs* 1999;20:333–55.
45. Decker MR, Silverman JG, Raj A. Dating violence and sexually transmitted disease/HIV testing and diagnosis among adolescent females. *Pediatrics* 2005;116:e272–6.
46. Fisher WA, Singh SS, Shuper PA, Carey M, Otchet F, MacLean-Brine D, et al. Characteristics of women undergoing repeat induced abortion. *CMAJ* 2005;172:637–41.
47. Gee RE, Mitra N, Wan F, Chavkin DE, Long JA. Power over parity: intimate partner violence and issues of fertility control. *Am J Obstet Gynecol* 2009;201:148.e1–7.
48. McFarlane J, Malecha A, Watson K, Gist J, Batten E, Hall I, et al. Intimate partner sexual assault against women: frequency, health consequences, and treatment outcomes. *Obstet Gynecol* 2005;105:99–108.
49. Miller E, Decker MR, McCauley HL, Tancredi DJ, Levenson RR, Waldman J, et al. Pregnancy coercion, intimate partner violence and unintended pregnancy. *Contraception* 2010;81:316–22.
50. Miller E, McCauley HL, Tancredi DJ, Decker MR, Anderson H, Silverman JG. Recent reproductive coercion and unintended pregnancy among female family planning clients. *Contraception* 2014;89:122–8.
51. Pallitto CC, Campbell JC, O'Campo P. Is intimate partner violence associated with unintended pregnancy? A review of the literature. *Trauma Violence Abuse* 2005;6:217–35.
52. Silverman JG, Decker MR, McCauley HL, Gupta J, Miller E, Raj A, et al. Male perpetration of intimate partner violence and involvement in abortions and abortion-related conflict. *Am J Public Health* 2010;100:1415–7.
53. Goenee MS, Donker GA, Picavet C, Wijssen C. Decision-making concerning unwanted pregnancy in general practice. *Fam Pract* 2014;31:564–70.
54. Guilbert É. Caractéristiques de 2829 femmes ayant obtenu un avortement à la clinique de planification des naissances du Centre Hospitalier de l'Université Laval. *Can J Public Health/Revue Canadienne de Santé Publique* 1993;28–30.
55. Visser M, Janssen A, Enschedé M, Willems A, te Braake TA, Harmsen K, et al. Evaluatie. Wet afbreking zwangerschap [Evaluation of the Law on Termination of Pregnancy]. The Hague, The Netherlands: 2005.
56. World Health Organization. *Clinical Practice Handbook for Safe Abortion*. Geneva, Switzerland: 2014.
57. Association of Reproductive Health Professionals. *Reproductive Health Topics: Abortion*. 2015;. Available at: <http://www.arhp.org/Topics/Abortion>. Accessed on October 23, 2015.
58. Davis VJ. Induced Abortion Guidelines. *JOGC* 2006;184:1014–27.
59. World Health Organization. *Safe abortion: technical and policy guidance for health systems*. Geneva, Switzerland: 2012.
60. Gould H, Foster DG, Perrucci AC, Barar RE, Roberts SC. Predictors of abortion counseling receipt and helpfulness in the United States. *Womens Health Issues* 2013;23:e249–55.
61. World Health Organization. *Frequently asked clinical questions about medical abortion*. World Health Organization; 2006.
62. Baron C, Cameron S, Johnstone A. Do women seeking termination of pregnancy need pre-abortion counselling? *J Fam Plann Reprod Health Care* 2015;41:181–5.
63. Brown S. Is counselling necessary? Making the decision to have an abortion. A qualitative interview study. *Eur J Contracept Reprod Health Care* 2013;18:44–8.
64. Finer LB, Frohworth LF, Dauphinee LA, Singh S, Moore AM. Reasons U.S. women have abortions: quantitative and qualitative perspectives. *Perspect Sex Reprod Health* 2005;37:110–8.
65. Kumar U, Baraitser P, Morton S, Massil H. Decision making and referral prior to abortion: a qualitative study of women's experiences. *J Fam Plann Reprod Health Care* 2004;30:51–4.
66. Canadian Medical Association. *Induced Abortion [CMA Policy]*. 1988.
67. Canadian Medical Protective Agency. *Thinking about a patient's human rights*. 2010;. Available at: https://www.cmpa-acpm.ca/en/legal-and-regulatory-proceedings/-/asset_publisher/a9unChEc2NP9/content/thinking-about-a-patient-s-human-rights. Accessed on October 23, 2015.
68. Black A, Guilbert É. Canadian contraception consensus. *J Obstet Gynaecol Can* 2015;37:936–8.
69. Blackmer J. Clarification of the CMA's position concerning induced abortion. *CMAJ* 2007;176:1310.
70. Sexuality Education Resource Center Manitoba. 2016;. Available at: <http://www.serc.mb.ca/sexual-health/pregnancy-options>. Accessed on February 9, 2016.
71. SOS Grossesse. 2016. Available at: <http://www.serc.mb.ca/sexual-health/pregnancy-options>. Accessed on February 9, 2016.
72. Bryant AG, Levi EE. Abortion misinformation from crisis pregnancy centers in North Carolina. *Contraception* 2012;86:752–6.
73. Glasier A, Thong JK. The establishment of a centralised referral service leads to earlier abortion. *Health Bull (Edinb)* 1991;49:254–9.
74. Norman WV, Hestrin B, Dueck R. Access to Complex Abortion Care Service and Planning Improved through a Toll-Free Telephone Resource Line. *Obstet Gynecol Int* 2014;2014:913241.
75. Medical management of first-trimester abortion. *Contraception* 2014;89:148–61.
76. Evans K, Henderson G. *Consent: a guide for Canadian physicians*. Ottawa: Canadian Medical Protective Association; 2006.
77. Guiahi M, Davis A, Society of Family P. First-trimester abortion in women with medical conditions: release date October 2012 SFP guideline #20122. *Contraception* 2012;86:622–30.
78. The efficacy and tolerance of mifepristone and prostaglandin in first trimester termination of pregnancy. *UK Multicentre Trial. Br J Obstet Gynaecol* 1990;97:480–6.

79. Baird DT, Sukcharoen N, Thong KJ. Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. *Hum Reprod* 1995;10:1521–7.
80. Creinin MD, Potter C, Holovanis M, Janczukiewicz L, Pymar HC, Schwartz JL, et al. Mifepristone and misoprostol and methotrexate/ misoprostol in clinical practice for abortion. *Am J Obstet Gynecol* 2003;188:664–9.
81. el-Refaei H, Rajasekar D, Abdalla M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. *N Engl J Med* 1995;332:983–7.
82. Tang OS, Chan CC, Ng EH, Lee SW, Ho PC. A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. *Hum Reprod* 2003;18:2315–8.
83. Winikoff B, Dzuba IG, Creinin MD, Crowden WA, Goldberg AB, Gonzales J, et al. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. *Obstet Gynecol* 2008;112:1303–10.
84. World Health Organization. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. *BJOG* 2000;107:524–30.
85. Ireland LD, Gatter M, Chen AY. Medical Compared With Surgical Abortion for Effective Pregnancy Termination in the First Trimester. *Obstet Gynecol* 2015;126:22–8.
86. Grossman D, White K, Harris L, Reeves M, Blumenthal PD, Winikoff B, et al. Continuing pregnancy after mifepristone and “reversal” of first-trimester medical abortion: a systematic review. *Contraception* 2015;92:206–11.
87. Zane S, Creanga AA, Berg CJ, Pazol K, Suchdev DB, Jamieson DJ, et al. Abortion-Related Mortality in the United States: 1998–2010. *Obstet Gynecol* 2015;126:258–65.
88. Blanchard K, Cooper D, Dickson K, Cullingworth L, Mavimbela N, von Mollendorf C, et al. A comparison of women’s, providers’ and ultrasound assessments of pregnancy duration among termination of pregnancy clients in South Africa. *BJOG* 2007;114:569–75.
89. McGalliard C, Gaudoin M. Routine ultrasound for pregnancy termination requests increases women’s choice and reduces inappropriate treatments. *BJOG* 2004;111:79–82.
90. Raymond EG, Bracken H. Early medical abortion without prior ultrasound. *Contraception* 2015;92:212–4.
91. Bracken H, Clark W, Lichtenberg ES, Schweikert SM, Tanenhaus J, Barajas A, et al. Alternatives to routine ultrasound for eligibility assessment prior to early termination of pregnancy with mifepristone-misoprostol. *BJOG* 2011;118:17–23.
92. Fakh MH, Barnea ER, Yarkoni S, DeCherney AH. The value of real time ultrasonography in first trimester termination. *Contraception* 1986;33:533–8.
93. Nichols M, Morgan E, Jensen JT. Comparing bimanual pelvic examination to ultrasound measurement for assessment of gestational age in the first trimester of pregnancy. *J Reprod Med* 2002;47:825–8.
94. Fielding SL, Schaff EA, Nam NY. Clinicians’ perception of sonogram indication for mifepristone abortion up to 63 days. *Contraception* 2002;66:27–31.
95. Goldstein SR, Wolfson R. Endovaginal ultrasonographic measurement of early embryonic size as a means of assessing gestational age. *J Ultrasound Med* 1994;13:27–31.
96. Paul M, Schaff E, Nichols M. The roles of clinical assessment, human chorionic gonadotropin assays, and ultrasonography in medical abortion practice. *Am J Obstet Gynecol* 2000;183:S34–43.
97. Kulier R, Kapp N. Comprehensive analysis of the use of pre-procedure ultrasound for first- and second-trimester abortion. *Contraception* 2011;83:30–3.
98. Linepharma International Limited. Product monograph including patient medication information. MIFEGYMISO. Submission Control No: 160063. 2015.
99. Bree RL, Edwards M, Bohm-Velez M, Beyler S, Roberts J, Mendelson EB. Transvaginal sonography in the evaluation of normal early pregnancy: correlation with HCG level. *AJR Am J Roentgenol* 1989;153:75–9.
100. Benson CB, Doubilet PM, Peters HE, Frates MC. Intrauterine fluid with ectopic pregnancy: a reappraisal. *J Ultrasound Med* 2013;32:389–93.
101. Doubilet PM, Benson CB, Bourne T, Blaivas M, for the Society of Radiologists in Ultrasound Multispecialty Panel on Early First Trimester Diagnosis of Miscarriage and Exclusion of a Viable Intrauterine Pregnancy. Diagnostic criteria for nonviable pregnancy early in the first trimester. *N Engl J Med* 2013;369:1443–51.
102. Butt K, Lim K. Society of Obstetricians and Gynaecologists of Canada. Determination of gestational age by ultrasound. *J Obstet Gynaecol Can* 2014;36:171–83.
103. Papaioannou GI, Syngelaki A, Poon LC, Ross JA, Nicolaides KH. Normal ranges of embryonic length, embryonic heart rate, gestational sac diameter and yolk sac diameter at 6–10 weeks. *Fetal Diagn Ther* 2010;28:207–19.
104. Creinin MD, Meyn L, Klimashko T. Accuracy of serum beta-human chorionic gonadotropin cutoff values at 42 and 49 days’ gestation. *Am J Obstet Gynecol* 2001;185:966–9.
105. Public Health Agency of Canada. Canadian Perinatal Health Report. Ottawa, ON. 2008.
106. Edwards J, Carson SA. New technologies permit safe abortion at less than six weeks’ gestation and provide timely detection of ectopic gestation. *Am J Obstet Gynecol* 1997;176:1101–6.
107. Hakim-Elahi E, Tovell HM, Burnhill MS. Complications of first-trimester abortion: a report of 170,000 cases. *Obstet Gynecol* 1990;76:129–35.
108. Cleland K, Creinin MD, Nucatola D, Nshom M, Trussell J. Significant adverse events and outcomes after medical abortion. *Obstet Gynecol* 2013;121:166–71.
109. American College of Obstetricians and Gynecologists. Practice bulletin no. 143: medical management of first-trimester abortion. *Obstet Gynecol* 2014;123:676–92.
110. National Abortion Federation. NAF Protocol for mifepristone/misoprostol in early abortion in the U.S. Washington, DC. 2013.
111. National Abortion Federation. 2014 Clinical Policy Guidelines. Washington, DC. 2014.
112. Barnhart K, van Mello NM, Bourne T, Kirk E, Van Calster B, Bottomley C, et al. Pregnancy of unknown location: a consensus statement of nomenclature, definitions, and outcome. *Fertil Steril* 2011;95:857–66.
113. Richardson A, Gallos I, Dobson S, Campbell BK, Coomarasamy A, Raine-Fenning N. Accuracy of first trimester ultrasound features for diagnosis of tubal ectopic pregnancy in the absence of an obvious extra-uterine embryo: A systematic review and meta-analysis. *Ultrasound Obstet Gynecol* 2015.
114. Condous G, Timmerman D, Goldstein S, Valentin L, Jurkovic D, Bourne T. Pregnancies of unknown location: consensus statement. *Ultrasound Obstet Gynecol* 2006;28:121–2.
115. Soon I, Cotescu D, Guilbert E. Evidence-based regimens for medical induced abortion. (Manuscript to be submitted). *JOGC* 2015.
116. Abbas D, Chong E, Raymond EG. Outpatient medical abortion is safe and effective through 70 days gestation. *Contraception* 2015;92:197–9.
117. Boersma AA, Meyboom-de Jong B, Kleiverda G. Mifepristone followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhoea in a general practice in Curacao. *Eur J Contracept Reprod Health Care* 2011;16:61–6.
118. Sanhueza Smith P, Pena M, Dzuba IG, Garcia Martinez ML, Arangue Peraza AG, Bousiequez M, et al. Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City. *Reprod Health Matters* 2015;22:75–82.

119. Davey A. Mifepristone and prostaglandin for termination of pregnancy: contraindications for use, reasons and rationale. *Contraception* 2006;74:16–20.
120. Cable EE, Pepe JA, Donohue SE, Lambrecht RW, Bonkovsky HL. Effects of mifepristone (RU-486) on heme metabolism and cytochromes P-450 in cultured chick embryo liver cells, possible implications for acute porphyria. *Eur J Biochem* 1994;225:651–7.
121. Sitruk-Ware R, Spitz IM. Pharmacological properties of mifepristone: toxicology and safety in animal and human studies. *Contraception* 2003;68:409–20.
122. Hausknecht R. Mifepristone and misoprostol for early medical abortion: 18 months experience in the United States. *Contraception* 2003;67:463–5.
123. Middleton T, Schaff E, Fielding SL, Scahill M, Shannon C, Westheimer E, et al. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. *Contraception* 2005;72:328–32.
124. Pena M, Dzuba IG, Smith PS, Mendoza LJ, Bousiequez M, Martinez ML, et al. Efficacy and acceptability of a mifepristone-misoprostol combined regimen for early induced abortion among women in Mexico City. *Int J Gynaecol Obstet* 2014;127:82–5.
125. Creinin MD, Schreiber CA, Bednarek P, Lintu H, Wagner MS, Meyn LA, et al. Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial. *Obstet Gynecol* 2007;109:885–94.
126. Schaff EA, Fielding SL, Eisinger SH, Stadius LS, Fuller L. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. *Contraception* 2000;61:41–6.
127. Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. *Contraception* 2001;64:81–5.
128. Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. *Contraception* 2002;66:247–50.
129. von Hertzen H, Huong NT, Piaggio G, Bayalag M, Cabezas E, Fang AH, et al. Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial. *BJOG* 2010;117:1186–96.
130. Creinin MD, Fox MC, Teal S, Chen A, Schaff EA, Meyn LA, et al. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. *Obstet Gynecol* 2004;103:851–9.
131. Kopp Kallner H, Fiala C, Stephansson O, Gemzell-Danielsson K. Home self-administration of vaginal misoprostol for medical abortion at 50–63 days compared with gestation of below 50 days. *Hum Reprod* 2010;25:1153–7.
132. Raymond EG, Shannon C, Weaver MA, Winikoff B. First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review. *Contraception* 2013;87:26–37.
133. Chen MJ, Creinin MD. Mifepristone with buccal misoprostol: A systematic review. *Obstet Gynecol* 2015;126:12–21.
134. Health Canada. Regulatory decision summary: MIFEGYMISO. 2012. Available at: www.hc-sc.gc.ca/dhp-mps/prodpharma/rds-sdr/drug-med/rds_sdr_mifegymiso_160063-eng.php. Accessed on September 11, 2015.
135. Yarnall J, Swica Y, Winikoff B. Non-physician clinicians can safely provide first trimester medical abortion. *Reprod Health Matters* 2009;17:61–9.
136. Grossman D, Goldstone P. Mifepristone by prescription: a dream in the United States but reality in Australia. *Contraception* 2015;92:186–9.
137. Chong E, Tsereteli T, Nguyen NN, Winikoff B. A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion. *Contraception* 2012;86:251–6.
138. Peyron R, Aubeny E, Targosz V, Silvestre L, Renault M, Elkik F, et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. *N Engl J Med* 1993;328:1509–13.
139. Silvestre L, Dubois C, Renault M, Rezvani Y, Baulieu EE, Ulmann A. Voluntary interruption of pregnancy with mifepristone (RU 486) and a prostaglandin analogue. A large-scale French experience. *N Engl J Med* 1990;322:645–8.
140. Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. *N Engl J Med* 1998;338:1241–7.
141. Ulmann A, Silvestre L, Chemama L, Rezvani Y, Renault M, Aguilhaume CJ, et al. Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue. Study in 16,369 women. *Acta Obstet Gynecol Scand* 1992;71:278–83.
142. Wiebe E, Dunn S, Guilbert E, Jacot F, Lugtig L. Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol. *Obstet Gynecol* 2002;99:813–9.
143. Akin A, Dabash R, Dilbaz B, Aktun H, Dursun P, Kiran S, et al. Increasing women's choices in medical abortion: a study of misoprostol 400 microg swallowed immediately or held sublingually following 200 mg mifepristone. *Eur J Contracept Reprod Health Care* 2009;14:169–75.
144. Cameron ST, Glasier A, Dewart H, Johnstone A, Burnside A. Telephone follow-up and self-performed urine pregnancy testing after early medical abortion: a service evaluation. *Contraception* 2012;86:67–73.
145. el-Refaey H, Templeton A. Early abortion induction by a combination of mifepristone and oral misoprostol: a comparison between two dose regimens of misoprostol and their effect on blood pressure. *Br J Obstet Gynaecol* 1994;101:792–6.
146. Knudsen UB. First trimester abortion with mifepristone and vaginal misoprostol. *Contraception* 2001;63:247–50.
147. Schaff EA, Fielding SL, Westhoff C, Ellertson C, Eisinger SH, Stadius LS, et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial. *JAMA* 2000;284:1948–53.
148. Shannon C, Wiebe E, Jacot F, Guilbert E, Dunn S, Sheldon WR, et al. Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial. *BJOG* 2006;113:621–8.
149. Kahn JG, Becker BJ, MacIsaac L, Amory JK, Neuhaus J, Olkin I, et al. The efficacy of medical abortion: a meta-analysis. *Contraception* 2000;61:29–40.
150. Bender N, Lopez NS, Nucatola D, Gatter M. Comparison of adverse events in the immediate perioperative period (within 8 weeks) after medication vs. surgical abortion. *Contraception* 2011;84:304.
151. Lichtenberg ES, Paul M, for the Society of Family Planning. Surgical abortion prior to 7 weeks of gestation. *Contraception* 2013;88:7–17.
152. Aldrich T, Winikoff B. Does methotrexate confer a significant advantage over misoprostol alone for early medical abortion? A retrospective analysis of 8678 abortions. *BJOG* 2007;114:555–62.
153. Creinin MD, Vittinghoff E, Galbraith S, Klaisle C. A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion. *Am J Obstet Gynecol* 1995;173:1578–84.
154. Schaff EA, Eisinger SH, Franks P, Kim SS. Combined methotrexate and misoprostol for early induced abortion. *Arch Fam Med* 1995;4:774–9.
155. Wiebe ER. Abortion induced with methotrexate and misoprostol. *CMAJ* 1996;154:165–70.
156. Carbonell I, Esteve JL, Velazco A, Varela L, Cabezas E, Fernandez C, Sanchez C. Misoprostol 3, 4, or 5 days after methotrexate for early abortion. A randomized trial. *Contraception* 1997;56:169–74.
157. Carbonell JL, Varela L, Velazco A, Cabezas E, Fernandez C, Sanchez C. Oral methotrexate and vaginal misoprostol for early abortion. *Contraception* 1998;57:83–8.
158. Hausknecht RU. Methotrexate and misoprostol to terminate early pregnancy. *N Engl J Med* 1995;333:537–40.
159. Ozeren M, Bilekli C, Aydemir V, Bozkaya H. Methotrexate and misoprostol used alone or in combination for early abortion. *Contraception* 1999;59:389–94.
160. von Hertzen H, Piaggio G, Huong NT, Arustamyan K, Cabezas E, Gomez M, et al. Efficacy of two intervals and two routes of

- administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial. *Lancet* 2007;369:1938–46.
161. Wiebe ER, Trouton K. Comparing vaginal and buccal misoprostol when used after methotrexate for early abortion. *Contraception* 2004;70:463–6.
 162. Carbonell JL, Rodriguez J, Velazco A, Tanda R, Sanchez C, Barambio S, et al. Oral and vaginal misoprostol 800 microg every 8 h for early abortion. *Contraception* 2003;67:457–62.
 163. Esteve JL, Varela L, Velazco A, Tanda R, Cabezas E, Sanchez C. Early abortion with 800 micrograms of misoprostol by the vaginal route. *Contraception* 1999;59:219–25.
 164. Bugalho A, Mocumbi S, Faundes A, David E. Termination of pregnancies of <6 weeks gestation with a single dose of 800 microg of vaginal misoprostol. *Contraception* 2000;61:47–50.
 165. Carbonell Esteve JL, Varela L, Velazco A, Cabezas E, Tanda R, Sanchez C. Vaginal misoprostol for late first trimester abortion. *Contraception* 1998;57:329–33.
 166. Carbonell JL, Varela L, Velazco A, Fernandez C. The use of misoprostol for termination of early pregnancy. *Contraception* 1997;55:165–8.
 167. Bamigboye AA, Nikodem VC, Santana MA, Hofmeyr GJ. Should women view the ultrasound image before first-trimester termination of pregnancy? *S Afr Med J* 2002;92:430–2.
 168. Gatter M, Kimport K, Foster DG, Weitz TA, Upadhyay UD. Relationship between ultrasound viewing and proceeding to abortion. *Obstet Gynecol* 2014;123:81–7.
 169. Wiebe ER, Adams L. Women's perceptions about seeing the ultrasound picture before an abortion. *Eur J Contracept Reprod Health Care* 2009;14:97–102.
 170. Fowler DJ, Lindsay I, Seckl MJ, Sebire NJ. Routine pre-evacuation ultrasound diagnosis of hydatidiform mole: experience of more than 1000 cases from a regional referral center. *Ultrasound Obstet Gynecol* 2006;27:56–60.
 171. Tidy JA, Gillespie AM, Bright N, Radstone CR, Coleman RE, Hancock BW. Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. *Gynecol Oncol* 2000;78:309–12.
 172. Hayes JL, Achilles SL, Creinin MD, Reeves MF. Outcomes of medical abortion through 63 days in women with twin gestations. *Contraception* 2011;84:505–7.
 173. Tulandi T, Al-Fozan H. Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation. UpToDate Inc [Updated 2011 June 2 Cited 2011 April]. Available at: <http://www.uptodate.com/contents/spontaneous-abortion-risk-factors-etiology-clinicalmanifestations-and-diagnostic-evaluation>. 2013.
 174. Committee on Practice Bulletins-Gynecology. The American College of Obstetricians and Gynecologists Practice Bulletin no. 150. Early pregnancy loss. *Obstet Gynecol* 2015;125:1258–67.
 175. International Federation of Gynecology and Obstetrics. Misoprostol Recommended Dosages. 2012. Available at: http://www.who.org/sites/default/files/uploads/project-publications/Miso/Misoprostol_Recommended%20Dosages%202012.pdf. Accessed on October 30, 2015.
 176. Gatter M, Cleland K, Nucatola DL. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. *Contraception* 2015;91:269–73.
 177. National Abortion Federation. Laboratory Practice Guideline #4. Washington, DC. 2015.
 178. Jabara S, Barnhart KT. Is Rh immune globulin needed in early first-trimester abortion? A review. *Am J Obstet Gynecol* 2003;188:623–7.
 179. Hamark B, Forssman L. Postabortal endometritis in chlamydia-negative women—association with preoperative clinical signs of infection. *Gynecol Obstet Invest* 1991;31:102–5.
 180. Stray-Pedersen B, Biornstad J, Dahl M, Bergan T, Aanestad G, Kristiansen L, et al. Induced abortion: microbiological screening and medical complications. *Infection* 1991;19:305–8.
 181. Fjerstad M, Trussell J, Sivin I, Lichtenberg ES, Cullins V. Rates of serious infection after changes in regimens for medical abortion. *N Engl J Med* 2009;361:145–51.
 182. Trussell J, Nucatola D, Fjerstad M, Lichtenberg ES. Reduction in infection-related mortality since modifications in the regimen of medical abortion. *Contraception* 2014;89:193–6.
 183. Lunny C, Taylor D, Hoang L, Wong T, Gilbert M, Lester R, et al. Self-Collected versus Clinician-Collected Sampling for Chlamydia and Gonorrhea Screening: A Systemic Review and Meta-Analysis. *PLoS One* 2015;10:e0132776.
 184. Wiesenfeld HC, Lowry DL, Heine RP, Krohn MA, Bittner H, Kellinger K, et al. Self-collection of vaginal swabs for the detection of Chlamydia, gonorrhea, and trichomoniasis: opportunity to encourage sexually transmitted disease testing among adolescents. *Sex Transm Dis* 2001;28:321–5.
 185. Goldstone P, Michelson J, Williamson E. Effectiveness of early medical abortion using low-dose mifepristone and buccal misoprostol in women with no defined intrauterine gestational sac. *Contraception* 2013;87:855–8.
 186. Schaff EA, Fielding SL, Eisinger S, Stadius L. Mifepristone and misoprostol for early abortion when no gestational sac is present. *Contraception* 2001;63:251–4.
 187. Wiebe ER. Methotrexate with or without misoprostol to terminate pregnancies with no gestational sac visible by ultrasound. *Int J Gynaecol Obstet* 2009;107:64–5.
 188. Bennett IM, Baylson M, Kalkstein K, Gillespie G, Bellamy SL, Fleischman J. Early abortion in family medicine: clinical outcomes. *Ann Fam Med* 2009;7:527–33.
 189. Barnhart KT. Clinical practice. Ectopic pregnancy. *N Engl J Med* 2009;361:379–87.
 190. Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. *Eur J Obstet Gynecol Reprod Biol* 2003;109:190–5.
 191. Stovall TG, Ling FW, Gray LA. Single-dose methotrexate for treatment of ectopic pregnancy. *Obstet Gynecol* 1991;77:754–7.
 192. Barnhart K, Hummel AC, Sammel MD, Menon S, Jain J, Chakhtoura N. Use of “2-dose” regimen of methotrexate to treat ectopic pregnancy. *Fertil Steril* 2007;87:250–6.
 193. Low N, Mueller M, Van Vliet HA, Kapp N. Perioperative antibiotics to prevent infection after first-trimester abortion. *Cochrane Database Syst Rev* 2012;3:CD005217.
 194. Sawaya GF, Grady D, Kerlikowske K, Grimes DA. Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. *Obstet Gynecol* 1996;87:884–90.
 195. Fjerstad M, Trussell J, Lichtenberg ES, Sivin I, Cullins V. Severity of infection following the introduction of new infection control measures for medical abortion. *Contraception* 2011;83:330–5.
 196. Ho CS, Bhatnagar J, Cohen AL, Hacker JK, Zane SB, Reagan S, et al. Undiagnosed cases of fatal Clostridium-associated toxic shock in Californian women of childbearing age. *Am J Obstet Gynecol* 2009;201:459.e1–7.
 197. Wiebe E, Guilbert E, Jacot F, Shannon C, Winikoff B. A fatal case of Clostridium sordellii septic shock syndrome associated with medical abortion. *Obstet Gynecol* 2004;104:1142–4.
 198. Clifford V, Daley A. Antibiotic prophylaxis in obstetric and gynaecological procedures: a review. *Aust N Z J Obstet Gynaecol* 2012;52:412–9.
 199. Frye LJ, Chong E, Winikoff B, NCT Trial Investigators. What happens when we routinely give doxycycline to medical abortion patients? *Contraception* 2015;91:19–24.
 200. Creinin MD, Danielsson KG. Medical abortion in early pregnancy. In: Paul M, Lichtenberg ES, Borgatta L, Grimes DA, Stubblefield PG, Creinin MD, editors. Management of unintended and abnormal pregnancy: comprehensive abortion care. Hoboken, NJ: Wiley-Blackwell; 2009. p. 111.

201. Hamoda H, Ashok PW, Flett GM, Templeton A. Analgesia requirements and predictors of analgesia use for women undergoing medical abortion up to 22 weeks of gestation. *BJOG* 2004;111:996–1000.
202. Livshits A, Machtinger R, David LB, Spira M, Moshe-Zahav A, Seidman DS. Ibuprofen and paracetamol for pain relief during medical abortion: a double-blind randomized controlled study. *Fertil Steril* 2009;91:1877–80.
203. Raymond EG, Weaver MA, Louie KS, Dean G, Porsch L, Lichtenberg ES, et al. Prophylactic compared with therapeutic ibuprofen analgesia in first-trimester medical abortion: a randomized controlled trial. *Obstet Gynecol* 2013;122:558–64.
204. Creinin MD, Shulman T. Effect of nonsteroidal anti-inflammatory drugs on the action of misoprostol in a regimen for early abortion. *Contraception* 1997;56:165–8.
205. Schaff EA, Stadius LS, Eisinger SH, Franks P. Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. *J Fam Pract* 1997;44:353–60.
206. Chai J, Wong CY, Ho PC. A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days' gestation. *Contraception* 2013;87:480–5.
207. Honkanen H, Piaggio G, Herten H, Bartfai G, Erdenetungalag R, Gemzell-Danielsson K, et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. *BJOG* 2004;111:715–25.
208. Bracken H, Lohr PA, Taylor J, Morroni C, Winikoff B. RU OK? The acceptability and feasibility of remote technologies for follow-up after early medical abortion. *Contraception* 2014;90:29–35.
209. Horning EL, Chen BA, Meyn LA, Creinin MD. Comparison of medical abortion follow-up with serum human chorionic gonadotropin testing and in-office assessment. *Contraception* 2012;85:402–7.
210. Dunn S, Panjwani D, Gupta M, Meaney C, Morgan R, Feuerstein E. Comparison of remote and in-clinic follow-up after methotrexate/misoprostol abortion. *Contraception* 2015;92:220–6.
211. Wiebe E, Fowler D, Trouton K, Fu N. Comparing patients' telephone calls after medical and surgical abortions. *Contraception* 2006;73:271–3.
212. Jackson AV, Dayananda I, Fortin JM, Fitzmaurice G, Goldberg AB. Can women accurately assess the outcome of medical abortion based on symptoms alone? *Contraception* 2012;85:192–7.
213. Rossi B, Creinin MD, Meyn LA. Ability of the clinician and patient to predict the outcome of mifepristone and misoprostol medical abortion. *Contraception* 2004;70:313–7.
214. Harper C, Ellertson C, Winikoff B. Could American women use mifepristone-misoprostol pills safely with less medical supervision? *Contraception* 2002;65:133–42.
215. Grossman D, Grindlay K. Alternatives to ultrasound for follow-up after medication abortion: a systematic review. *Contraception* 2011;83:504–10.
216. Kaneshiro B, Edelman A, Sneeringer RK, Ponce de Leon RG. Expanding medical abortion: can medical abortion be effectively provided without the routine use of ultrasound? *Contraception* 2011;83:194–201.
217. Clark W, Bracken H, Tanenhaus J, Schweikert S, Lichtenberg ES, Winikoff B. Alternatives to a routine follow-up visit for early medical abortion. *Obstet Gynecol* 2010;115:264–72.
218. Ngoc NT, Bracken H, Blum J, Nga NT, Minh NH, van Nhang N, et al. Acceptability and feasibility of phone follow-up after early medical abortion in Vietnam: a randomized controlled trial. *Obstet Gynecol* 2014;123:88–95.
219. Clark W, Panton T, Hann L, Gold M. Medication abortion employing routine sequential measurements of serum hCG and sonography only when indicated. *Contraception* 2007;75:131–5.
220. Harwood B, Meckstroth KR, Mishell DR, Jain JK. Serum beta-human chorionic gonadotropin levels and endometrial thickness after medical abortion. *Contraception* 2001;63:255–6.
221. Reeves MF, Fox MC, Lohr PA, Creinin MD. Endometrial thickness following medical abortion is not predictive of subsequent surgical intervention. *Ultrasound Obstet Gynecol* 2009;34:104–9.
222. Dayananda I, Maurer R, Fortin J, Goldberg AB. Medical abortion follow-up with serum human chorionic gonadotropin compared with ultrasonography: a randomized controlled trial. *Obstet Gynecol* 2013;121:607–13.
223. Creinin MD. Change in serum beta-human chorionic gonadotropin after abortion with methotrexate and misoprostol. *Am J Obstet Gynecol* 1996;174:776–8.
224. Honkanen H, Ranta S, Ylikorkala O, Heikinheimo O. The kinetics of serum hCG and progesterone in response to oral and vaginal administration of misoprostol during medical termination of early pregnancy. *Hum Reprod* 2002;17:2315–9.
225. Pocius KD, Maurer R, Fortin J, Goldberg AB, Bartz D. Early serum human chorionic gonadotropin (hCG) trends after medication abortion. *Contraception* 2015;91:503–6.
226. Walker K, Schaff E, Fielding S, Fuller L. Monitoring serum chorionic gonadotropin levels after mifepristone abortion. *Contraception* 2001;64:271–3.
227. Michie L, Cameron ST. Simplified follow-up after early medical abortion: 12-month experience of a telephone call and self-performed low-sensitivity urine pregnancy test. *Contraception* 2014;89:440–5.
228. Godfrey EM, Anderson A, Fielding SL, Meyn L, Creinin MD. Clinical utility of urine pregnancy assays to determine medical abortion outcome is limited. *Contraception* 2007;75:378–82.
229. Cameron ST, Glasier A, Johnstone A, Dewart H, Campbell A. Can women determine the success of early medical termination of pregnancy themselves? *Contraception* 2015;91:6–11.
230. Perriera LK, Reeves MF, Chen GA, Hohmann HL, Hayes J, Creinin MD. Feasibility of telephone follow-up after medical abortion. *Contraception* 2010;81:143–9.
231. Acharya G, Haugen M, Brathen A, Nilsen I, Maltau JM. Role of routine ultrasonography in monitoring the outcome of medical abortion in a clinical setting. *Acta Obstet Gynecol Scand* 2004;83:390–4.
232. Cowett AA, Cohen LS, Lichtenberg ES, Stika CS. Ultrasound evaluation of the endometrium after medical termination of pregnancy. *Obstet Gynecol* 2004;103:871–5.
233. Napolitano R, Ghosh M, Gillott DJ, Ojha K. Three-dimensional Doppler sonography in asymptomatic and symptomatic women after medical termination of pregnancy. *J Ultrasound Med* 2014;33:847–52.
234. Reeves MF, Kudva A, Creinin MD. Medical abortion outcomes after a second dose of misoprostol for persistent gestational sac. *Contraception* 2008;78:332–5.
235. Church E, Sengupta S, Chia KV. The contraceptive implant for long acting reversible contraception in patients undergoing first trimester medical termination of pregnancy. *Sex Reprod Healthc* 2010;1:105–9.
236. Shannon C, Brothers LP, Philip NM, Winikoff B. Infection after medical abortion: a review of the literature. *Contraception* 2004;70:183–90.
237. Kruse B, Poppema S, Creinin MD, Paul M. Management of side effects and complications in medical abortion. *Am J Obstet Gynecol* 2000;183:S65–75.
238. Sitruk-Ware R. Mifepristone and misoprostol sequential regimen side effects, complications and safety. *Contraception* 2006;74:48–55.
239. Public Health Agency of Canada. Canadian Guidelines on Sexually Transmitted Infections. 2015. Available at: <http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-lcdcits/index-eng.php>. Accessed on September 25, 2015.
240. Cohen AL, Bhatnagar J, Reagan S, Zane SB, D'Angeli MA, Fischer M, et al. Toxic shock associated with *Clostridium sordellii* and *Clostridium perfringens* after medical and spontaneous abortion. *Obstet Gynecol* 2007;110:1027–33.
241. Daif JL, Levie M, Chudnoff S, Kaiser B, Shahabi S. Group A Streptococcus causing necrotizing fasciitis and toxic shock syndrome after medical termination of pregnancy. *Obstet Gynecol* 2009;113:504–6.

242. Fischer M, Bhatnagar J, Guarner J, Reagan S, Hacker JK, Van Meter SH, et al. Fatal toxic shock syndrome associated with *Clostridium sordellii* after medical abortion. *N Engl J Med* 2005;353:2352–60.
243. Gendron N, Joubrel C, Nedellec S, Campagna J, Agostini A, Doucet-Populaire F, et al. Group A *Streptococcus* endometritis following medical abortion. *J Clin Microbiol* 2014;52:2733–5.
244. Sinave C, Le Templier G, Blouin D, Leveille F, Deland E. Toxic shock syndrome due to *Clostridium sordellii*: a dramatic postpartum and postabortion disease. *Clin Infect Dis* 2002;35:1441–3.
245. Chong E, Winikoff B, Charles D, Agnew K, Prentice JL, Limbago BM, et al. Vaginal and rectal *Clostridium sordellii* and *Clostridium perfringens* presence among women in the United States. *Obstet Gynecol Int* 2016;127:1–10.
246. Aldape MJ, Bryant AE, Stevens DL. *Clostridium sordellii* infection: epidemiology, clinical findings, and current perspectives on diagnosis and treatment. *Clin Infect Dis* 2006;43:1436–46.
247. Dempsey A. Serious infection associated with induced abortion in the United States. *Clin Obstet Gynecol* 2012;55:888–92.
248. McGregor JA, Equils O. Response to letter to the editor. *Contraception* 2006;74:175–6.
249. Soper DE. Abortion and clostridial toxic shock syndrome. *Obstet Gynecol* 2007;110:970–1.
250. Creinin MD. Conception rates after abortion with methotrexate and misoprostol. *Int J Gynaecol Obstet* 1999;65:183–8.
251. Chen A, Yuan W, Meirik O, Wang X, Wu SZ, Zhou L, et al. Mifepristone-induced early abortion and outcome of subsequent wanted pregnancy. *Am J Epidemiol* 2004;160:110–7.
252. Virk J, Zhang J, Olsen J. Medical abortion and the risk of subsequent adverse pregnancy outcomes. *N Engl J Med* 2007;357:648–53.
253. Oliver-Williams C, Fleming M, Monteath K, Wood AM, Smith GC. Changes in association between previous therapeutic abortion and preterm birth in Scotland, 1980 to 2008: a historical cohort study. *PLoS Med* 2013;10:e1001481.
254. Schreiber CA, Sober S, Ratcliffe S, Creinin MD. Ovulation resumption after medical abortion with mifepristone and misoprostol. *Contraception* 2011;84:230–3.
255. Micks E, Prager S. Plan A: postabortion contraception. *Clin Obstet Gynecol* 2014;57:751–62.
256. Centers for Disease Control Prevention. U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. *MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports/ Centers for Disease Control*. 2010;59:1.
257. Centers for Disease Control Prevention. U.S. selected practice recommendations for contraceptive use, 2013. *MMWR Recomm Rep* 2013;62:1–64.
258. Tang OS, Gao PP, Cheng L, Lee SW, Ho PC. A randomized double-blind placebo-controlled study to assess the effect of oral contraceptive pills on the outcome of medical abortion with mifepristone and misoprostol. *Hum Reprod* 1999;14:722–5.
259. Tang OS, Xu J, Cheng L, Lee SW, Ho PC. The effect of contraceptive pills on the measured blood loss in medical termination of pregnancy by mifepristone and misoprostol: a randomized placebo controlled trial. *Hum Reprod* 2002;17:99–102.
260. Fine PM, Tryggstad J, Meyers NJ, Sangi-Haghepeykar H. Safety and acceptability with the use of a contraceptive vaginal ring after surgical or medical abortion. *Contraception* 2007;75:367–71.
261. Sonalkar S, Hou MY, Borgatta L. Administration of the etonogestrel contraceptive implant on the day of mifepristone for medical abortion: a pilot study. *Contraception* 2013;88:671–3.
262. Brache V, Cochin L, Duijkers IJ, Levy DP, Kapp N, Monteil C, et al. A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception. *Hum Reprod* 2015.
263. Sonalkar S, McClusky J, Hou MY, Borgatta L. Administration of depot medroxyprogesterone acetate on the day of mifepristone for medical abortion: a pilot study. *Contraception* 2015;91:174–7.
264. Raymond J, Weaver MA, Tan YL, Louie K, Bousiequez M, Lugo-Hernandez EM, et al. Effect of immediate compared with delayed insertion of etonogestrel implants on medical abortion efficacy and repeat pregnancy: a randomized controlled trial. *Obstet Gynecol* 2016;127:306–12.
265. Betstadt SJ, Turok DK, Kapp N, Feng KT, Borgatta L. Intrauterine device insertion after medical abortion. *Contraception* 2011;83:517–21.
266. Saav I, Stephansson O, Gemzell-Danielsson K. Early versus delayed insertion of intrauterine contraception after medical abortion - a randomized controlled trial. *PLoS One* 2012;7:e48948.
267. Shimoni N, Davis A, Ramos ME, Rosario L, Westhoff C. Timing of copper intrauterine device insertion after medical abortion: a randomized controlled trial. *Obstet Gynecol* 2011;118:623–8.
268. Shimoni N, Davis A, Westhoff C. Can ultrasound predict IUD expulsion after medical abortion? *Contraception* 2014;89:434–9.
269. Major B, Appelbaum M, Beckman L, Dutton MA, Russo NF, West C. Abortion and mental health: Evaluating the evidence. *Am Psychol* 2009;64:863–90.
270. Munk-Olsen T, Laursen TM, Pedersen CB, Lidegaard O, Mortensen PB. Induced first-trimester abortion and risk of mental disorder. *N Engl J Med* 2011;364:332–9.
271. Steinberg JR, Becker D, Henderson JT. Does the outcome of a first pregnancy predict depression, suicidal ideation, or lower self-esteem? Data from the National Comorbidity Survey. *Am J Orthop* 2011;81:193–201.
272. Charles VE, Polis CB, Sridhara SK, Blum RW. Abortion and long-term mental health outcomes: a systematic review of the evidence. *Contraception* 2008;78:436–50.
273. Kendall T, Bird V, Cantwell R, Taylor C. To meta-analyse or not to meta-analyse: abortion, birth and mental health. *Br J Psychiatry* 2012;200:12–4.
274. Major B, Appelbaum M, Beckman L, Dutton MA, Russo NF, West C. Mental health and abortion. Washington, DC, USA: Report of the American Psychological Association; 2008.
275. Academy of Medical Royal Colleges. National Collaborating Centre for Mental Health. Induced Abortion and Mental Health: A Systematic Review of the Mental Health Outcomes of Induced Abortion, Including Their Prevalence and Associated Factors: Executive Summary. 2011. Available at: http://www.aomrc.org.uk/doc_view/9432-induced-abortion-and-mental-health. Accessed on November 30, 2015.
276. van Ditzhuijzen J, Ten Have M, de Graaf R, van Nijnatten CH, Vollebergh WA. The impact of psychiatric history on women's pre- and postabortion experiences. *Contraception* 2015;92:246–53.
277. O'Connor AM, Jacobsen MJ, Stacey D. An evidence-based approach to managing women's decisional conflict. *J Obstet Gynecol Neonatal Nurs* 2002;31:570–81.
278. Warren JT, Harvey SM, Henderson JT. Do depression and low self-esteem follow abortion among adolescents? Evidence from a national study. *Perspect Sex Reprod Health* 2010;42:230–5.
279. Weitz TA, Cockrill K. Abortion clinic patients' opinions about obtaining abortions from general women's health care providers. *Patient Educ Couns* 2010;81:409–14.